JP2012036112A - Method for manufacturing product for improving bioavailability, and the product - Google Patents
Method for manufacturing product for improving bioavailability, and the product Download PDFInfo
- Publication number
- JP2012036112A JP2012036112A JP2010176026A JP2010176026A JP2012036112A JP 2012036112 A JP2012036112 A JP 2012036112A JP 2010176026 A JP2010176026 A JP 2010176026A JP 2010176026 A JP2010176026 A JP 2010176026A JP 2012036112 A JP2012036112 A JP 2012036112A
- Authority
- JP
- Japan
- Prior art keywords
- mineral
- promoting composition
- dietary fiber
- absorption promoting
- mineral absorption
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000004519 manufacturing process Methods 0.000 title claims description 21
- 238000000034 method Methods 0.000 title abstract description 15
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 170
- 239000011707 mineral Substances 0.000 claims abstract description 170
- 150000001875 compounds Chemical class 0.000 claims abstract description 56
- 210000004369 blood Anatomy 0.000 claims abstract description 46
- 239000008280 blood Substances 0.000 claims abstract description 46
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 45
- 239000011575 calcium Substances 0.000 claims abstract description 45
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 45
- 239000004094 surface-active agent Substances 0.000 claims abstract description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 17
- 235000013311 vegetables Nutrition 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims description 111
- 238000010521 absorption reaction Methods 0.000 claims description 109
- 230000001737 promoting effect Effects 0.000 claims description 61
- 239000003921 oil Substances 0.000 claims description 55
- 235000013325 dietary fiber Nutrition 0.000 claims description 50
- 239000003925 fat Substances 0.000 claims description 46
- -1 fatty acid ester Chemical class 0.000 claims description 30
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 24
- 239000000194 fatty acid Substances 0.000 claims description 24
- 229930195729 fatty acid Natural products 0.000 claims description 24
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 18
- 239000007901 soft capsule Substances 0.000 claims description 17
- 239000004615 ingredient Substances 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 12
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 11
- 239000011777 magnesium Substances 0.000 claims description 11
- 229910052749 magnesium Inorganic materials 0.000 claims description 11
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims description 10
- 235000013402 health food Nutrition 0.000 claims description 10
- 235000013305 food Nutrition 0.000 claims description 9
- 229910052742 iron Inorganic materials 0.000 claims description 9
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 235000013376 functional food Nutrition 0.000 claims description 8
- 229920001353 Dextrin Polymers 0.000 claims description 7
- 239000004375 Dextrin Substances 0.000 claims description 7
- 235000019425 dextrin Nutrition 0.000 claims description 7
- 229910052698 phosphorus Inorganic materials 0.000 claims description 7
- 239000011574 phosphorus Substances 0.000 claims description 7
- 229920002907 Guar gum Polymers 0.000 claims description 6
- 235000010418 carrageenan Nutrition 0.000 claims description 6
- 239000000679 carrageenan Substances 0.000 claims description 6
- 229920001525 carrageenan Polymers 0.000 claims description 6
- 229940113118 carrageenan Drugs 0.000 claims description 6
- 239000000665 guar gum Substances 0.000 claims description 6
- 235000010417 guar gum Nutrition 0.000 claims description 6
- 229960002154 guar gum Drugs 0.000 claims description 6
- 229920005610 lignin Polymers 0.000 claims description 6
- 239000003002 pH adjusting agent Substances 0.000 claims description 6
- 239000001814 pectin Substances 0.000 claims description 6
- 229920001277 pectin Polymers 0.000 claims description 6
- 235000010987 pectin Nutrition 0.000 claims description 6
- 239000004014 plasticizer Substances 0.000 claims description 6
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 6
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 5
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 5
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 5
- 229920001100 Polydextrose Polymers 0.000 claims description 5
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 5
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 5
- 235000013361 beverage Nutrition 0.000 claims description 5
- 229910052804 chromium Inorganic materials 0.000 claims description 5
- 239000011651 chromium Substances 0.000 claims description 5
- 229910052802 copper Inorganic materials 0.000 claims description 5
- 239000010949 copper Substances 0.000 claims description 5
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 5
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 5
- 239000001259 polydextrose Substances 0.000 claims description 5
- 235000013856 polydextrose Nutrition 0.000 claims description 5
- 229940035035 polydextrose Drugs 0.000 claims description 5
- 239000011591 potassium Substances 0.000 claims description 5
- 229910052700 potassium Inorganic materials 0.000 claims description 5
- 229910052711 selenium Inorganic materials 0.000 claims description 5
- 239000011669 selenium Substances 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- 239000011701 zinc Substances 0.000 claims description 5
- 229910052725 zinc Inorganic materials 0.000 claims description 5
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 claims description 4
- 229910017052 cobalt Inorganic materials 0.000 claims description 4
- 239000010941 cobalt Substances 0.000 claims description 4
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 229910052751 metal Inorganic materials 0.000 claims description 4
- 239000002184 metal Substances 0.000 claims description 4
- 229910052750 molybdenum Inorganic materials 0.000 claims description 4
- 239000011733 molybdenum Substances 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 229910052720 vanadium Inorganic materials 0.000 claims description 4
- GPPXJZIENCGNKB-UHFFFAOYSA-N vanadium Chemical compound [V]#[V] GPPXJZIENCGNKB-UHFFFAOYSA-N 0.000 claims description 4
- OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 claims description 3
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 claims description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 3
- 229920000936 Agarose Polymers 0.000 claims description 3
- 229920002101 Chitin Polymers 0.000 claims description 3
- 229920001661 Chitosan Polymers 0.000 claims description 3
- 229920002567 Chondroitin Polymers 0.000 claims description 3
- 229920000855 Fucoidan Polymers 0.000 claims description 3
- 229920000926 Galactomannan Polymers 0.000 claims description 3
- 108010010803 Gelatin Proteins 0.000 claims description 3
- 229920001503 Glucan Polymers 0.000 claims description 3
- 229920002581 Glucomannan Polymers 0.000 claims description 3
- 229920002488 Hemicellulose Polymers 0.000 claims description 3
- 229920001202 Inulin Polymers 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- 235000010443 alginic acid Nutrition 0.000 claims description 3
- 239000000783 alginic acid Substances 0.000 claims description 3
- 229920000615 alginic acid Polymers 0.000 claims description 3
- 229960001126 alginic acid Drugs 0.000 claims description 3
- 150000004781 alginic acids Chemical class 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 claims description 3
- 239000007857 degradation product Substances 0.000 claims description 3
- 229940105990 diglycerin Drugs 0.000 claims description 3
- 239000008273 gelatin Substances 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims description 3
- 229940046240 glucomannan Drugs 0.000 claims description 3
- 229940029339 inulin Drugs 0.000 claims description 3
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 3
- 235000010413 sodium alginate Nutrition 0.000 claims description 3
- 239000000661 sodium alginate Substances 0.000 claims description 3
- 229940005550 sodium alginate Drugs 0.000 claims description 3
- 235000002316 solid fats Nutrition 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 claims description 2
- 238000000576 coating method Methods 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 abstract description 11
- 239000000835 fiber Substances 0.000 abstract 1
- 235000010755 mineral Nutrition 0.000 description 137
- 235000019198 oils Nutrition 0.000 description 49
- 229960005069 calcium Drugs 0.000 description 42
- 235000019197 fats Nutrition 0.000 description 40
- 238000009472 formulation Methods 0.000 description 23
- 238000003756 stirring Methods 0.000 description 19
- 239000000047 product Substances 0.000 description 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 13
- 239000000843 powder Substances 0.000 description 13
- 235000021419 vinegar Nutrition 0.000 description 13
- 239000000052 vinegar Substances 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 241000700159 Rattus Species 0.000 description 11
- 238000004945 emulsification Methods 0.000 description 11
- 230000003631 expected effect Effects 0.000 description 11
- 229940092124 calcium citrate malate Drugs 0.000 description 10
- MPCMQXRREZMSPJ-UHFFFAOYSA-L calcium;2-hydroxybutanedioate;2-hydroxypropane-1,2,3-tricarboxylic acid;pentahydrate Chemical compound O.O.O.O.O.[Ca+2].[O-]C(=O)C(O)CC([O-])=O.OC(=O)CC(O)(C(O)=O)CC(O)=O MPCMQXRREZMSPJ-UHFFFAOYSA-L 0.000 description 10
- 239000010459 dolomite Substances 0.000 description 10
- 229910000514 dolomite Inorganic materials 0.000 description 10
- 229940091250 magnesium supplement Drugs 0.000 description 10
- 210000001035 gastrointestinal tract Anatomy 0.000 description 9
- 235000011187 glycerol Nutrition 0.000 description 9
- 230000036541 health Effects 0.000 description 9
- 229930003316 Vitamin D Natural products 0.000 description 8
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 229960003284 iron Drugs 0.000 description 8
- 235000019166 vitamin D Nutrition 0.000 description 8
- 239000011710 vitamin D Substances 0.000 description 8
- 150000003710 vitamin D derivatives Chemical class 0.000 description 8
- 229940046008 vitamin d Drugs 0.000 description 8
- 239000005018 casein Substances 0.000 description 7
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 7
- 235000021240 caseins Nutrition 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000000704 physical effect Effects 0.000 description 6
- JHYAVWJELFKHLM-UHFFFAOYSA-H tetrasodium;2-hydroxypropane-1,2,3-tricarboxylate;iron(2+) Chemical compound [Na+].[Na+].[Na+].[Na+].[Fe+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O JHYAVWJELFKHLM-UHFFFAOYSA-H 0.000 description 6
- 235000015112 vegetable and seed oil Nutrition 0.000 description 6
- 239000008158 vegetable oil Substances 0.000 description 6
- 108010001441 Phosphopeptides Proteins 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 210000000988 bone and bone Anatomy 0.000 description 5
- 229940043430 calcium compound Drugs 0.000 description 5
- 150000001674 calcium compounds Chemical class 0.000 description 5
- 235000014593 oils and fats Nutrition 0.000 description 5
- 210000000813 small intestine Anatomy 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 4
- 239000010775 animal oil Substances 0.000 description 4
- 229940108928 copper Drugs 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 235000008390 olive oil Nutrition 0.000 description 4
- 239000004006 olive oil Substances 0.000 description 4
- 229960003975 potassium Drugs 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 229940091258 selenium supplement Drugs 0.000 description 4
- 229940083542 sodium Drugs 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108010078791 Carrier Proteins Proteins 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 3
- 240000007594 Oryza sativa Species 0.000 description 3
- 235000007164 Oryza sativa Nutrition 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 235000015278 beef Nutrition 0.000 description 3
- 229940107218 chromium Drugs 0.000 description 3
- 150000001845 chromium compounds Chemical class 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 238000003305 oral gavage Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 235000009566 rice Nutrition 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 239000003760 tallow Substances 0.000 description 3
- 235000019871 vegetable fat Nutrition 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 2
- 239000005749 Copper compound Substances 0.000 description 2
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 2
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 240000008415 Lactuca sativa Species 0.000 description 2
- 239000000232 Lipid Bilayer Substances 0.000 description 2
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 235000019482 Palm oil Nutrition 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 244000098338 Triticum aestivum Species 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 2
- ANVAOWXLWRTKGA-XHGAXZNDSA-N all-trans-alpha-carotene Chemical compound CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1C(C)=CCCC1(C)C ANVAOWXLWRTKGA-XHGAXZNDSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 235000021329 brown rice Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 description 2
- 229940110767 coenzyme Q10 Drugs 0.000 description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 150000001880 copper compounds Chemical class 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 102000038379 digestive enzymes Human genes 0.000 description 2
- 108091007734 digestive enzymes Proteins 0.000 description 2
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 2
- 229940090949 docosahexaenoic acid Drugs 0.000 description 2
- 239000008157 edible vegetable oil Substances 0.000 description 2
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 2
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 2
- 235000020774 essential nutrients Nutrition 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 235000007144 ferric diphosphate Nutrition 0.000 description 2
- 239000011706 ferric diphosphate Substances 0.000 description 2
- CADNYOZXMIKYPR-UHFFFAOYSA-B ferric pyrophosphate Chemical compound [Fe+3].[Fe+3].[Fe+3].[Fe+3].[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O CADNYOZXMIKYPR-UHFFFAOYSA-B 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 150000002497 iodine compounds Chemical class 0.000 description 2
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 2
- 235000008696 isoflavones Nutrition 0.000 description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 2
- 230000002366 lipolytic effect Effects 0.000 description 2
- 230000001926 lymphatic effect Effects 0.000 description 2
- 150000002681 magnesium compounds Chemical class 0.000 description 2
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 2
- 150000002697 manganese compounds Chemical class 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000002540 palm oil Substances 0.000 description 2
- 238000005192 partition Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 235000011007 phosphoric acid Nutrition 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 150000003112 potassium compounds Chemical class 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 229940065287 selenium compound Drugs 0.000 description 2
- 150000003343 selenium compounds Chemical class 0.000 description 2
- 150000003388 sodium compounds Chemical class 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 150000003752 zinc compounds Chemical class 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- CBOJBBMQJBVCMW-BTVCFUMJSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;hydrochloride Chemical class Cl.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO CBOJBBMQJBVCMW-BTVCFUMJSA-N 0.000 description 1
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- AEQDJSLRWYMAQI-UHFFFAOYSA-N 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- PMYDPQQPEAYXKD-UHFFFAOYSA-N 3-hydroxy-n-naphthalen-2-ylnaphthalene-2-carboxamide Chemical compound C1=CC=CC2=CC(NC(=O)C3=CC4=CC=CC=C4C=C3O)=CC=C21 PMYDPQQPEAYXKD-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000019737 Animal fat Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000512259 Ascophyllum nodosum Species 0.000 description 1
- 235000012137 Atriplex confertifolia Nutrition 0.000 description 1
- 244000266618 Atriplex confertifolia Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 239000001736 Calcium glycerylphosphate Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 235000014653 Carica parviflora Nutrition 0.000 description 1
- 244000132059 Carica parviflora Species 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical compound [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 1
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 description 1
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 1
- 229920002079 Ellagic acid Polymers 0.000 description 1
- OEIJRRGCTVHYTH-UHFFFAOYSA-N Favan-3-ol Chemical compound OC1CC2=CC=CC=C2OC1C1=CC=CC=C1 OEIJRRGCTVHYTH-UHFFFAOYSA-N 0.000 description 1
- 239000004277 Ferrous carbonate Substances 0.000 description 1
- PMVSDNDAUGGCCE-TYYBGVCCSA-L Ferrous fumarate Chemical compound [Fe+2].[O-]C(=O)\C=C\C([O-])=O PMVSDNDAUGGCCE-TYYBGVCCSA-L 0.000 description 1
- DKKCQDROTDCQOR-UHFFFAOYSA-L Ferrous lactate Chemical compound [Fe+2].CC(O)C([O-])=O.CC(O)C([O-])=O DKKCQDROTDCQOR-UHFFFAOYSA-L 0.000 description 1
- CITFYDYEWQIEPX-UHFFFAOYSA-N Flavanol Natural products O1C2=CC(OCC=C(C)C)=CC(O)=C2C(=O)C(O)C1C1=CC=C(O)C=C1 CITFYDYEWQIEPX-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 235000019487 Hazelnut oil Nutrition 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 235000003228 Lactuca sativa Nutrition 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 240000002834 Paulownia tomentosa Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- HLCFGWHYROZGBI-JJKGCWMISA-M Potassium gluconate Chemical compound [K+].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O HLCFGWHYROZGBI-JJKGCWMISA-M 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 235000019774 Rice Bran oil Nutrition 0.000 description 1
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 1
- ZONYXWQDUYMKFB-UHFFFAOYSA-N SJ000286395 Natural products O1C2=CC=CC=C2C(=O)CC1C1=CC=CC=C1 ZONYXWQDUYMKFB-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 235000019498 Walnut oil Nutrition 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 1
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 1
- FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- CANRESZKMUPMAE-UHFFFAOYSA-L Zinc lactate Chemical compound [Zn+2].CC(O)C([O-])=O.CC(O)C([O-])=O CANRESZKMUPMAE-UHFFFAOYSA-L 0.000 description 1
- OOIOHEBTXPTBBE-UHFFFAOYSA-N [Na].[Fe] Chemical compound [Na].[Fe] OOIOHEBTXPTBBE-UHFFFAOYSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- ZOJBYZNEUISWFT-UHFFFAOYSA-N allyl isothiocyanate Chemical compound C=CCN=C=S ZOJBYZNEUISWFT-UHFFFAOYSA-N 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 239000011795 alpha-carotene Substances 0.000 description 1
- 235000003903 alpha-carotene Nutrition 0.000 description 1
- ANVAOWXLWRTKGA-HLLMEWEMSA-N alpha-carotene Natural products C(=C\C=C\C=C(/C=C/C=C(\C=C\C=1C(C)(C)CCCC=1C)/C)\C)(\C=C\C=C(/C=C/[C@H]1C(C)=CCCC1(C)C)\C)/C ANVAOWXLWRTKGA-HLLMEWEMSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- FRHBOQMZUOWXQL-UHFFFAOYSA-L ammonium ferric citrate Chemical compound [NH4+].[Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FRHBOQMZUOWXQL-UHFFFAOYSA-L 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229960002713 calcium chloride Drugs 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 229960004256 calcium citrate Drugs 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- 229940095618 calcium glycerophosphate Drugs 0.000 description 1
- UHHRFSOMMCWGSO-UHFFFAOYSA-L calcium glycerophosphate Chemical compound [Ca+2].OCC(CO)OP([O-])([O-])=O UHHRFSOMMCWGSO-UHFFFAOYSA-L 0.000 description 1
- 235000019299 calcium glycerylphosphate Nutrition 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 1
- 239000000292 calcium oxide Substances 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 150000001869 cobalt compounds Chemical class 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 229940116318 copper carbonate Drugs 0.000 description 1
- 229910000009 copper(II) carbonate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
- GEZOTWYUIKXWOA-UHFFFAOYSA-L copper;carbonate Chemical compound [Cu+2].[O-]C([O-])=O GEZOTWYUIKXWOA-UHFFFAOYSA-L 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000019854 cupric carbonate Nutrition 0.000 description 1
- 239000011646 cupric carbonate Substances 0.000 description 1
- 235000019855 cupric citrate Nutrition 0.000 description 1
- 239000011641 cupric citrate Substances 0.000 description 1
- 235000019856 cupric gluconate Nutrition 0.000 description 1
- 239000011642 cupric gluconate Substances 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- HBYOLNPZXLHVQA-UHFFFAOYSA-J dicalcium dicarbonate Chemical compound [Ca+2].[Ca+2].[O-]C([O-])=O.[O-]C([O-])=O HBYOLNPZXLHVQA-UHFFFAOYSA-J 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- CHFUHGDBYUITQJ-UHFFFAOYSA-L dipotassium;2,3-dihydroxypropyl phosphate Chemical compound [K+].[K+].OCC(O)COP([O-])([O-])=O CHFUHGDBYUITQJ-UHFFFAOYSA-L 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 210000003278 egg shell Anatomy 0.000 description 1
- 235000004132 ellagic acid Nutrition 0.000 description 1
- 229960002852 ellagic acid Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960004642 ferric ammonium citrate Drugs 0.000 description 1
- 229940036404 ferric pyrophosphate Drugs 0.000 description 1
- 235000019268 ferrous carbonate Nutrition 0.000 description 1
- RAQDACVRFCEPDA-UHFFFAOYSA-L ferrous carbonate Chemical compound [Fe+2].[O-]C([O-])=O RAQDACVRFCEPDA-UHFFFAOYSA-L 0.000 description 1
- 229960004652 ferrous carbonate Drugs 0.000 description 1
- 235000019850 ferrous citrate Nutrition 0.000 description 1
- 239000011640 ferrous citrate Substances 0.000 description 1
- 235000002332 ferrous fumarate Nutrition 0.000 description 1
- 239000011773 ferrous fumarate Substances 0.000 description 1
- 229960000225 ferrous fumarate Drugs 0.000 description 1
- 235000013924 ferrous gluconate Nutrition 0.000 description 1
- 239000004222 ferrous gluconate Substances 0.000 description 1
- 229960001645 ferrous gluconate Drugs 0.000 description 1
- 235000013925 ferrous lactate Nutrition 0.000 description 1
- 239000004225 ferrous lactate Substances 0.000 description 1
- 229940037907 ferrous lactate Drugs 0.000 description 1
- 229960001781 ferrous sulfate Drugs 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 229940013317 fish oils Drugs 0.000 description 1
- 235000011987 flavanols Nutrition 0.000 description 1
- 229930003949 flavanone Natural products 0.000 description 1
- 150000002207 flavanone derivatives Chemical class 0.000 description 1
- 235000011981 flavanones Nutrition 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
- 150000007946 flavonol Chemical class 0.000 description 1
- 235000011957 flavonols Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000008169 grapeseed oil Substances 0.000 description 1
- 239000010468 hazelnut oil Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 235000000011 iron ammonium citrate Nutrition 0.000 description 1
- 239000004313 iron ammonium citrate Substances 0.000 description 1
- 150000002506 iron compounds Chemical class 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000015 iron(II) carbonate Inorganic materials 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- APVZWAOKZPNDNR-UHFFFAOYSA-L iron(ii) citrate Chemical compound [Fe+2].OC(=O)CC(O)(C([O-])=O)CC([O-])=O APVZWAOKZPNDNR-UHFFFAOYSA-L 0.000 description 1
- VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical compound [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 235000011285 magnesium acetate Nutrition 0.000 description 1
- 239000011654 magnesium acetate Substances 0.000 description 1
- 229940069446 magnesium acetate Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229960001708 magnesium carbonate Drugs 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229960002337 magnesium chloride Drugs 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 235000015778 magnesium gluconate Nutrition 0.000 description 1
- 239000001755 magnesium gluconate Substances 0.000 description 1
- 229960003035 magnesium gluconate Drugs 0.000 description 1
- 235000001130 magnesium glycerophosphate Nutrition 0.000 description 1
- 239000011742 magnesium glycerophosphate Substances 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- OVGXLJDWSLQDRT-UHFFFAOYSA-L magnesium lactate Chemical compound [Mg+2].CC(O)C([O-])=O.CC(O)C([O-])=O OVGXLJDWSLQDRT-UHFFFAOYSA-L 0.000 description 1
- 235000015229 magnesium lactate Nutrition 0.000 description 1
- 239000000626 magnesium lactate Substances 0.000 description 1
- 229960004658 magnesium lactate Drugs 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 229960003390 magnesium sulfate Drugs 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- IAKLPCRFBAZVRW-XRDLMGPZSA-L magnesium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;hydrate Chemical compound O.[Mg+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IAKLPCRFBAZVRW-XRDLMGPZSA-L 0.000 description 1
- BHJKUVVFSKEBEX-UHFFFAOYSA-L magnesium;2,3-dihydroxypropyl phosphate Chemical compound [Mg+2].OCC(O)COP([O-])([O-])=O BHJKUVVFSKEBEX-UHFFFAOYSA-L 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 235000006748 manganese carbonate Nutrition 0.000 description 1
- 239000011656 manganese carbonate Substances 0.000 description 1
- 229940093474 manganese carbonate Drugs 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 229910000016 manganese(II) carbonate Inorganic materials 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- XMWCXZJXESXBBY-UHFFFAOYSA-L manganese(ii) carbonate Chemical compound [Mn+2].[O-]C([O-])=O XMWCXZJXESXBBY-UHFFFAOYSA-L 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000021243 milk fat Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000005078 molybdenum compound Substances 0.000 description 1
- 150000002752 molybdenum compounds Chemical class 0.000 description 1
- 150000004712 monophosphates Chemical class 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 239000008164 mustard oil Substances 0.000 description 1
- NALMPLUMOWIVJC-UHFFFAOYSA-N n,n,4-trimethylbenzeneamine oxide Chemical compound CC1=CC=C([N+](C)(C)[O-])C=C1 NALMPLUMOWIVJC-UHFFFAOYSA-N 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229960002969 oleic acid Drugs 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 229960004838 phosphoric acid Drugs 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 235000002378 plant sterols Nutrition 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 229940094025 potassium bicarbonate Drugs 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229940093956 potassium carbonate Drugs 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 229960002816 potassium chloride Drugs 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 235000013926 potassium gluconate Nutrition 0.000 description 1
- 239000004224 potassium gluconate Substances 0.000 description 1
- 229960003189 potassium gluconate Drugs 0.000 description 1
- 235000000491 potassium glycerophosphate Nutrition 0.000 description 1
- 239000011600 potassium glycerophosphate Substances 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 235000011118 potassium hydroxide Nutrition 0.000 description 1
- JLKDVMWYMMLWTI-UHFFFAOYSA-M potassium iodate Chemical compound [K+].[O-]I(=O)=O JLKDVMWYMMLWTI-UHFFFAOYSA-M 0.000 description 1
- 235000006666 potassium iodate Nutrition 0.000 description 1
- 239000001230 potassium iodate Substances 0.000 description 1
- 229940093930 potassium iodate Drugs 0.000 description 1
- 229960004839 potassium iodide Drugs 0.000 description 1
- 235000007715 potassium iodide Nutrition 0.000 description 1
- PHZLMBHDXVLRIX-UHFFFAOYSA-M potassium lactate Chemical compound [K+].CC(O)C([O-])=O PHZLMBHDXVLRIX-UHFFFAOYSA-M 0.000 description 1
- 235000011085 potassium lactate Nutrition 0.000 description 1
- 239000001521 potassium lactate Substances 0.000 description 1
- 229960001304 potassium lactate Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000008165 rice bran oil Substances 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000012045 salad Nutrition 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 235000012207 sodium gluconate Nutrition 0.000 description 1
- 239000000176 sodium gluconate Substances 0.000 description 1
- 229940005574 sodium gluconate Drugs 0.000 description 1
- 235000013271 sodium hydrogen selenite Nutrition 0.000 description 1
- 239000011792 sodium hydrogen selenite Substances 0.000 description 1
- 235000015281 sodium iodate Nutrition 0.000 description 1
- 239000011697 sodium iodate Substances 0.000 description 1
- 229940032753 sodium iodate Drugs 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 229940083599 sodium iodide Drugs 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 235000018716 sodium selenate Nutrition 0.000 description 1
- 239000011655 sodium selenate Substances 0.000 description 1
- 229960001881 sodium selenate Drugs 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- 229940074404 sodium succinate Drugs 0.000 description 1
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 1
- OHYAUPVXSYITQV-UHFFFAOYSA-M sodium;hydrogen selenite Chemical compound [Na+].O[Se]([O-])=O OHYAUPVXSYITQV-UHFFFAOYSA-M 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 210000001321 subclavian vein Anatomy 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 210000004210 tooth component Anatomy 0.000 description 1
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- STDMRMREKPZQFJ-UHFFFAOYSA-H tricopper;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Cu+2].[Cu+2].[Cu+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O STDMRMREKPZQFJ-UHFFFAOYSA-H 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 229910000406 trisodium phosphate Inorganic materials 0.000 description 1
- 235000019801 trisodium phosphate Nutrition 0.000 description 1
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 description 1
- 150000003682 vanadium compounds Chemical class 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000008170 walnut oil Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000010698 whale oil Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010930 zeaxanthin Nutrition 0.000 description 1
- 239000001775 zeaxanthin Substances 0.000 description 1
- 229940043269 zeaxanthin Drugs 0.000 description 1
- 239000004246 zinc acetate Substances 0.000 description 1
- 229960000314 zinc acetate Drugs 0.000 description 1
- 235000013904 zinc acetate Nutrition 0.000 description 1
- 235000004416 zinc carbonate Nutrition 0.000 description 1
- 239000011667 zinc carbonate Substances 0.000 description 1
- 229910000010 zinc carbonate Inorganic materials 0.000 description 1
- 229940043825 zinc carbonate Drugs 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 229960001939 zinc chloride Drugs 0.000 description 1
- 235000006076 zinc citrate Nutrition 0.000 description 1
- 239000011746 zinc citrate Substances 0.000 description 1
- 229940068475 zinc citrate Drugs 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
- 229960000306 zinc gluconate Drugs 0.000 description 1
- 235000000193 zinc lactate Nutrition 0.000 description 1
- 239000011576 zinc lactate Substances 0.000 description 1
- 229940050168 zinc lactate Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 229960001296 zinc oxide Drugs 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
Images
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Non-Alcoholic Beverages (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
本発明は、「医薬品」、「特定保健用食品」、「いわゆる健康食品」および食品、飲料及び菓子などへの利用が期待されるミネラル吸収促進組成物、及びその製造方法に関する。 The present invention relates to a “medicine”, “food for specified health use”, “so-called health food” and a mineral absorption promoting composition expected to be used for foods, beverages and confectionery, and a method for producing the same.
「医薬品」、「特定保健用食品」、「いわゆる健康食品」などに含まれる機能性成分を生物学的に効率よく吸収し、生物学的利用能(バイオアベイラビリティー)を向上させるため、様々な試みがなされてきた。「医薬品」、「特定保健用食品」、「いわゆる健康食品」などに含まれる機能性成分のうち、親水性機能性成分は、その物性上小腸柔毛細胞の毛細血管からの吸収に優れ、血中移行も速やかであることが知られている。また、親油性機能性成分は消化管内で分泌される脂質分解酵素により分解され、脂肪酸とのエステル体の形態で小腸のリンパ管より吸収され、鎖骨下静脈を経て血中に移行して吸収されることが知られている。そこで、それぞれの物性の違いから、異なった吸収経路に合った配合処方にすることで、吸収を効率化させる試みがなされてきた。例えば、特許文献1には親油性機能性成分であるコエンザイムQ10を油に分散し消化酵素と組み合わせる技術が公開されている。また特許文献2には、吸収性向上を目的に機能性成分をイオン化し、微細化(マイクロ化、ナノ化)する技術が公開されている。
In order to absorb biologically efficient functional ingredients contained in “pharmaceuticals”, “food for specified health use”, “so-called health foods”, etc., and improve bioavailability, various Attempts have been made. Among the functional ingredients contained in “pharmaceuticals”, “special health foods”, “so-called health foods”, etc., hydrophilic functional ingredients are excellent in absorption from capillaries of small intestinal fur cells due to their physical properties. It is known that the transition to the middle is quick. In addition, lipophilic functional components are degraded by lipolytic enzymes secreted in the digestive tract, absorbed in the form of esters with fatty acids from the lymph vessels of the small intestine, transferred to the blood via the subclavian vein, and absorbed. It is known that Therefore, attempts have been made to improve the absorption efficiency by making the formulation suitable for different absorption routes due to the difference in physical properties. For example,
このような技術開発経緯のもと現在のDDS(Drug Delivery System)の理論では、油水分配係数に着目した考え方や、機能性成分の粒径の影響によって機能性成分の吸収速度が変わり、血中への移行や細胞への取り込み方が違ってくるという考え方が、一般的になっている。消化管からの吸収を考えると、親水性機能成分(油水分配係数が1以下で小さいほど親水性である)は、小腸柔毛細胞の毛細血管から血中に取り込まれ、体内を循環するが、親油性機能性成分(油水分配係数が1以上で大きいものほど親油性である)は、消化管の中でエマルションやミセルの形態で微粒子化されたものが消化管の柔毛細胞におけるリンパ管吸収を経て血中に移行すると考えられる。
また、細胞内への取り込みに際しては、細胞膜が脂質二重膜構造になっている関係で親油性のものほど細胞内への取り込みが速やかに行われ、親水性のものは、脂質二重膜表面の脂質によってはじかれてしまう。従って、血中への移行は親水性機能性成分のほうが速く、細胞内への取り込みは親油性機能性成分のほうが良いと言えるのかもしれない。
Based on this history of technological development, the current DDS (Drug Delivery System) theory is based on the idea of focusing on the oil-water distribution coefficient and the effect of the particle size of the functional component on the absorption rate of the functional component. The notion that migration to cells and uptake into cells are different has become common. Considering absorption from the gastrointestinal tract, the hydrophilic functional component (the smaller the oil-water partition coefficient is 1, the lower the hydrophilicity) is taken into the blood from the capillaries of small intestinal fur cells and circulates in the body. The lipophilic functional component (the higher the oil-water partition coefficient is 1 or higher, the more lipophilic) the finer particles in the digestive tract in the form of emulsions or micelles are absorbed by the lymphatic vessels in the fur cells of the digestive tract. It is thought that it goes into the blood via this.
In addition, when taking up into the cell, the lipophilic one is more rapidly taken into the cell because the cell membrane has a lipid bilayer structure, and the hydrophilic one is the lipid bilayer surface. It will be repelled by the lipids. Therefore, it may be said that the hydrophilic functional component is faster in the blood and the lipophilic functional component is better in the cellular uptake.
そのような観点から、多相エマルション製剤が開発されており、特許文献3には、W/Oエマルション調整の第1工程、S/Oサスペンション調整の第2工程、S/O/W系多相エマルション調整の第3工程、S/O/W系多相エマルションを膜透過で50〜1000nmに粒径を整える第4工程からなる多相エマルション製剤により機能性成分を安定的に標的細胞部位に送達する技術が公開されている。
しかし、これら特許技術文献1〜3などに公開されている技術では、機能性成分の物性の影響を受けるという問題や、機能性成分の微細化(マイクロ化、ナノ化)する工程やS/O/W系の多相エマルションの調整工程などが必要で生産性が劣るという問題が未解決のままであった。
From such a viewpoint, multi-phase emulsion preparations have been developed. Patent Document 3 describes the first step of W / O emulsion adjustment, the second step of S / O suspension adjustment, and the S / O / W multi-phase. Functional component is stably delivered to the target cell site by the multi-phase emulsion formulation consisting of the third step of emulsion adjustment, the fourth step of adjusting the particle size of the S / O / W multi-phase emulsion to 50-1000 nm by membrane permeation Technology to do is released.
However, in the technologies disclosed in these patent
一方、本発明者らは鋭意研究を続け、親水性機能性成分及び親油性機能性成分の両方について、血中濃度曲線下面積(AUC)、血中最高濃度到達時間(Tmax)、血中最高濃度(Cmax)などの血中動態を測定することにより、配合助剤によって親水性機能性成分の血中動態が変化して、生物学的利用能(バイオアベイラビリティー)が向上することを確認し特許出願に及んでいる(特許文献4)。 On the other hand, the present inventors have continued intensive research, and for both hydrophilic functional components and lipophilic functional components, the area under the blood concentration curve (AUC), the time to reach the highest concentration in blood (Tmax), the highest in blood By measuring the blood kinetics such as concentration (Cmax), it was confirmed that the blood kinetics of the hydrophilic functional component was changed by the combination aid, and bioavailability was improved. It has reached patent applications (Patent Document 4).
しかし、ヒトにとって必須の栄養成分であるミネラルを効率的に吸収するという問題は未解決のままであった。とりわけカルシウムは体重の1〜2%を占め、その99%がハイドロキシアパタイトとして骨及び歯に存在する重要なミネラルであり、そのカルシウム吸収量が不足すると、骨量が減少し、骨粗鬆症が引き起こされる。しかし、日本の土壌にはカルシウム成分が少ないことから、食物からの摂取だけでは十分な量が取られていないことが以前から指摘されていた。そのため、カルシウムの吸収を助けるビタミンDを配合した牛乳や、カルシウムの溶解性に影響を与えるCCM(クエン酸リンゴ酸カルシウム)を配合した特定保健用機能食品の飲料や、カルシウムと結合し吸収を促進するCPP(カゼインホスホペプチド)を配合した特定保健用機能食品の飲料などが開発され製品化されている(非特許文献1 p170)。しかし、ビタミンDは、保存、調理、加工中に分解されてしまい、ビタミンD強化牛乳に光を当てると40%のビタミンDが分解されてしまう問題があった。また、CCM(クエン酸リンゴ酸カルシウム)やCPP(カゼインホスホペプチド)を配合する製品では、溶解性を高める必要があるため飲料の形態でなければ、期待する効果が十分に得られないという問題を抱えていた。
However, the problem of efficiently absorbing minerals, which are essential nutrients for humans, remained unresolved. In particular, calcium accounts for 1-2% of body weight, 99% of which is an important mineral present in bones and teeth as hydroxyapatite. When the amount of calcium absorption is insufficient, bone mass is reduced and osteoporosis is caused. However, it has been pointed out for a long time that food intake alone is not enough because of the low calcium content of Japanese soil. For this reason, milk containing vitamin D that helps absorb calcium, drinks of functional foods for specified health use containing CCM (calcium citrate malate) that affects the solubility of calcium, and binding to calcium promotes absorption. Beverages of functional foods for specific health that contain CPP (casein phosphopeptide) to be developed have been developed and commercialized (Non-patent
そこで本発明は、機能性成分の物性に関係なく、機能性成分を微細化(マイクロ化、ナノ化)する工程や、水に分散又は溶解する工程、あるいはS/O/W系の多相エマルションのような調整工程なども必要なく、簡便な方法で機能性成分を効率的に血中に移行させ血中濃度曲線下面積(AUC)を上昇させることで、生物学的利用能(バイオアベイラビリティー)を向上させる技術を提供することを目的とする。
特に機能性成分としてカルシウムなどのミネラルを含有するミネラル化合物を、ビタミンD、CCM(クエン酸リンゴ酸カルシウム)、CPP(カゼインホスホペプチド)などの吸収促進補助材を配合すことなく、微細化(マイクロ化、ナノ化)する工程や、水に分散又は溶解する工程、あるいはS/O/W系の多相エマルションのような調整工程なども必要なく、従来に無い簡便な方法で効率的に血中に移行させ血中濃度曲線下面積(AUC)を上昇させることで、生物学的利用能(バイオアベイラビリティー)を向上させる技術を提供することを目的とする。
Therefore, the present invention is not limited to the physical properties of the functional component, the step of making the functional component fine (micro, nano), the step of dispersing or dissolving in water, or the S / O / W multiphase emulsion. The bioavailability (bioavailability) is improved by efficiently transferring functional components into the blood and increasing the area under the blood concentration curve (AUC) by a simple method. ) To improve the technology.
In particular, a mineral compound containing a mineral such as calcium as a functional component is refined without adding an absorption promotion auxiliary material such as vitamin D, CCM (calcium citrate malate), or CPP (casein phosphopeptide). And nano-scale), dispersion or dissolution in water, and adjustment steps such as S / O / W multi-phase emulsions are not required, and blood can be efficiently and easily used It aims at providing the technique which improves bioavailability (bioavailability) by making it move to (2) and raising the area under a blood concentration curve (AUC).
本発明者らは、鋭意研究を重ねた結果、カルシウム化合物などのミネラル化合物を含むミネラル吸収促進組成物を調整するにあたり、ミネラル化合物と油脂と界面活性剤と食物繊維の組み合わせによって、ミネラルを効率的に血中に移行させ血中濃度曲線下面積(AUC)を上昇させることで、生物学的利用能(バイオアベイラビリティー)を向上させることを見出し、本発明を完成させた。
従って、本願は下記の発明を包含する。
(1) 機能性成分としてミネラル化合物を含む組成物を調整するにあたり、ミネラル化合物と油脂と界面活性剤を組み合わせることによって、ミネラルの血中濃度曲線下面積(AUC)を向上させることのできるミネラル吸収促進組成物の製造方法。
As a result of intensive studies, the present inventors have made efficient use of minerals by combining mineral compounds, fats and oils, surfactants, and dietary fiber in preparing a mineral absorption promoting composition containing mineral compounds such as calcium compounds. The present inventors have found that bioavailability (bioavailability) can be improved by transferring to the blood and increasing the area under the blood concentration curve (AUC).
Therefore, this application includes the following invention.
(1) Mineral absorption that can improve the area under the blood concentration curve (AUC) of minerals by combining mineral compounds, fats and oils, and surfactants when preparing compositions containing mineral compounds as functional ingredients A method of making the acceleration composition.
(2) 前記ミネラル化合物が、カルシウム、マグネシウム、鉄、亜鉛、カリウム、クロム、セレン、銅、ナトリウム、マンガン、ヨウ素、リン、モリブデン、コバルト、バナジウム、の化合物から選ばれるいずれか1種類又は2種類以上の組み合わせで、そのミネラル化合物の配合量がミネラル吸収促進組成物全体に対し1〜60重量%であり、
前記ミネラル吸収促進組成物を調整するにあたり、ミネラル化合物と油脂と界面活性剤のほか、更に食物繊維を組み合わせ、
これらミネラル化合物と、油脂と、界面活性剤と、食物繊維を、高速攪拌機または高速粉砕機を用いて、回転数2000〜8000rpmで10〜100分間攪拌処理し均一化することを特徴とする、(1)のミネラル吸収促進組成物の製造方法。
(2) The mineral compound is one or two selected from compounds of calcium, magnesium, iron, zinc, potassium, chromium, selenium, copper, sodium, manganese, iodine, phosphorus, molybdenum, cobalt, and vanadium. In the above combination, the compounding amount of the mineral compound is 1 to 60% by weight with respect to the whole mineral absorption promoting composition,
In preparing the mineral absorption promoting composition, in addition to mineral compounds, fats and oils, surfactants, and further combining dietary fiber,
These mineral compounds, fats and oils, surfactants, and dietary fibers are stirred and homogenized at a rotational speed of 2000 to 8000 rpm for 10 to 100 minutes using a high speed stirrer or a high speed grinder. The manufacturing method of the mineral absorption promotion composition of 1).
(3)前記界面活性剤が、モノグリセリン脂肪酸エステル、ジグリセリン脂肪酸エステル、ポリグリセリン脂肪酸エステル、ショ糖脂肪酸エステル、ソルビタン脂肪酸エステルの群から選ばれる1種類又は2種類以上の組み合わせで、その配合量がミネラル吸収促進組成物全体に対し、1〜30重量%であり、
前記油脂が、液体状油と固体状脂の群から選ばれる1種類又は2種類以上の組み合わせで、その配合量が1〜80重量%であり、
前記食物繊維が、水溶性食物繊維、または不溶性食物繊維、または水溶性食物繊維及び不溶性食物繊維の組み合わせであり、その配合量がミネラル吸収促進組成物全体に対し、1〜20重量%であり、
前記水溶性食物繊維が、難消化性デキストリン、ポリデキストロース、アルギン酸、低分子化アルギン酸ナトリウム、ガラクトマンナン、グルコマンナン、水溶性ペクチン、フコイダン、グアガム、グアガム分解物、水溶性リグニン、コンドロイチンの群から選ばれる1種類又は2種類以上の組み合わせであり、
前記不溶性食物繊維が、セルロース、ふすま、ヘミセルロース、不溶性ペクチン、不溶性リグニン、グルカン、イヌリン、カラギーナン、アガロース、キチン、キトサンの群から選ばれる1種類又は2種類以上の組み合わせであることを特徴とする、(1)または(2)のミネラル吸収促進組成物の製造方法。
(3) The surfactant is one or a combination of two or more selected from the group of monoglycerol fatty acid ester, diglycerol fatty acid ester, polyglycerol fatty acid ester, sucrose fatty acid ester and sorbitan fatty acid ester, Is 1 to 30% by weight based on the whole mineral absorption promoting composition,
The fats and oils are one or a combination of two or more selected from the group of liquid oils and solid fats, and the blending amount is 1 to 80% by weight,
The dietary fiber is a water-soluble dietary fiber, or an insoluble dietary fiber, or a combination of a water-soluble dietary fiber and an insoluble dietary fiber, and the amount of the dietary fiber is 1 to 20% by weight based on the whole mineral absorption promoting composition,
The water-soluble dietary fiber is selected from the group of indigestible dextrin, polydextrose, alginic acid, low molecular weight sodium alginate, galactomannan, glucomannan, water-soluble pectin, fucoidan, guar gum, guar gum degradation product, water-soluble lignin, chondroitin One type or a combination of two or more types,
The insoluble dietary fiber is one or a combination of two or more selected from the group of cellulose, bran, hemicellulose, insoluble pectin, insoluble lignin, glucan, inulin, carrageenan, agarose, chitin, chitosan, (1) The manufacturing method of the mineral absorption promotion composition of (2).
(4) 前記ミネラル吸収促進組成物を調整するにあたり、ミネラル化合物と油脂と界面活性剤と食物繊維のほか、更にpH調整剤を組み合わせたことを特徴とする、(1)〜(3)のいずれかのミネラル吸収促進組成物の製造方法。 (4) Any one of (1) to (3), characterized in that in addition to mineral compounds, fats and oils, surfactants and dietary fibers, a pH adjuster is further combined in preparing the mineral absorption promoting composition. A method for producing such a mineral absorption promoting composition.
(5) 前記ミネラル吸収促進組成物を調整するにあたり、機能性成分として、ミネラル化合物の他、更に親水性機能性成分、親油性機能性成分の群から選ばれる1種類又は2種類以上の組み合わせを含有することを特徴とする、(1)〜(4)のいずれかのミネラル吸収促進組成物の製造方法。 (5) In preparing the mineral absorption promoting composition, as a functional component, in addition to a mineral compound, one or a combination of two or more selected from the group of a hydrophilic functional component and a lipophilic functional component. The manufacturing method of the mineral absorption promotion composition in any one of (1)-(4) characterized by containing.
(6) (1)〜(5)のいずれかの製造方法によって製造されたミネラル吸収促進組成物。 (6) The mineral absorption promotion composition manufactured by the manufacturing method in any one of (1)-(5).
(7) (1)〜(6)のいずれかの製造方法によって製造されたミネラル吸収促進組成物を含有する医薬品、医薬部外品、機能性食品、健康食品、食品飲料。 (7) A pharmaceutical, a quasi-drug, a functional food, a health food, and a food drink containing the mineral absorption promoting composition produced by the production method of any one of (1) to (6).
(8) 前記ミネラル吸収促進組成物を含むカプセル内容物をソフトな皮膜で被覆してなるソフトカプセルにおいて、
前記ソフトカプセル皮膜部は、ゼラチン、可塑剤(グリセリンなど)、水を配合した皮膜、または、でんぷん、カラギーナン、可塑剤(グリセリンなど)、金属塩、水を配合した植物性皮膜からなり、前記ミネラル吸収促進組成物を含むソフトカプセル内容物を調整するにあたり、(1)〜(5)のいずれかのミネラル吸収促進組成物の製造方法によって、ミネラルの血中濃度曲線下面積(AUC)を向上させたソフトカプセル。
(8) In a soft capsule formed by coating a capsule content containing the mineral absorption promoting composition with a soft film,
The soft capsule film part is a film containing gelatin, plasticizer (such as glycerin) and water, or a vegetable film blended with starch, carrageenan, plasticizer (such as glycerin), metal salt, and water. Soft capsules that improve the area under the blood concentration curve (AUC) of minerals by the method for producing a mineral absorption promoting composition according to any one of (1) to (5) in preparing the soft capsule content containing the promoting composition .
(9) 前記ソフトカプセルが、医薬品、医薬部外品、機能性食品、健康食品であることを特徴とする、(8)のソフトカプセル。 (9) The soft capsule according to (8), wherein the soft capsule is a pharmaceutical, a quasi-drug, a functional food, or a health food.
本発明は、カルシウム化合物などのミネラル化合物に対し、油脂と界面活性剤と食物繊維を組み合わせることにより、ミネラルを効率的に血中に移行させ血中濃度曲線下面積(AUC)を上昇させることで、生物学的利用能(バイオアベイラビリティー)を向上させることが可能となる。
そのため、本発明ではミネラルが極めて効率良く生体内に吸収され、そのため高価なミネラル化合物の使用量を大幅に低減しても、従来の場合と比べて同等或いはそれ以上の効果を期待することができる。また得られるミネラル吸収促進組成物は、粉末状でも顆粒状でも、或いはそれを打錠して錠剤状、或いはそれをソフトカプセル、ハードカプセルに充填された状態でも良いが、どのような態様においても低容量化、ローコスト化することができる。
In the present invention, minerals such as calcium compounds are combined with fats and oils, surfactants and dietary fibers to efficiently transfer minerals into the blood and increase the area under the blood concentration curve (AUC). It is possible to improve the bioavailability (bioavailability).
Therefore, in the present invention, the mineral is absorbed into the living body very efficiently, and therefore, even if the amount of expensive mineral compound used is greatly reduced, an effect equivalent to or higher than that of the conventional case can be expected. . Further, the obtained mineral absorption promoting composition may be in the form of powder or granule, or may be tableted by tableting it, or filled in soft capsules or hard capsules. And low cost.
本発明者らは、鋭意研究を重ねた結果、カルシウム化合物などのミネラル化合物を含むミネラル吸収促進組成物を調整するにあたり、ミネラル化合物と油脂と界面活性剤と食物繊維の組み合わせによって、ミネラルを効率的に血中に移行させ血中濃度曲線下面積(AUC)を上昇させることで、生物学的利用能(バイオアベイラビリティー)を向上させることを見出し、本発明を完成させた。
本発明のミネラル吸収促進組成物は、油脂と、界面活性剤と、食物繊維と、ミネラル化合物と、からなる。以下に、本発明の作用原理及び本発明の、油脂と、界面活性剤と、食物繊維と、ミネラル化合物のそれぞれについて説明する。
As a result of intensive studies, the present inventors have made efficient use of minerals by combining mineral compounds, fats and oils, surfactants, and dietary fiber in preparing a mineral absorption promoting composition containing mineral compounds such as calcium compounds. The present inventors have found that bioavailability (bioavailability) can be improved by transferring to the blood and increasing the area under the blood concentration curve (AUC).
The mineral absorption promotion composition of this invention consists of fats and oils, surfactant, dietary fiber, and a mineral compound. Below, each of the action principle of this invention and the fats and oils, surfactant, dietary fiber, and mineral compound of this invention is demonstrated.
<本発明の作用原理>
本発明の作用原理は必ずしも明らかではないが、消化管内で分泌される脂質分解酵素により分解される油脂を用いることで、脂肪酸などの「油脂消化分解物」が生成される。この新たに生成される「油脂消化分解物」と、界面活性剤と、食物繊維と、ミネラルが消化管内でエマルション又はミセル化することで、小腸粘膜と相互作用し、親水性機能性成分の小腸柔毛の毛細血管吸収経路と、油脂と同様の小腸のリンパ管吸収経路の両方の消化吸収が可能になると考えられる。そして、親水性機能性成分の「小腸柔毛の毛細血管吸収」と親油性機能性成分の「小腸のリンパ管吸収」の相乗効果により、ミネラルの消化管吸収が促進され、生物学的利用能が向上すると考えられる。
また、消化管粘膜上皮細胞に存在する機能性成分のトランスポーター(P糖たんぱく質)は、一度膜透過した機能性成分を再び小腸管内に汲みだしてしまうトランスポーターであるが、本発明の油脂と界面活性剤と食物繊維の組み合わせで、このトランスポーターの働きを阻害することにより、ミネラルの消化管吸収が促進されると考えられる。
さらに、CYP3A4に代表されるシトクロムP450(CYP)3A分子種の腸管内代謝酵素の働きを、本発明の油脂と界面活性剤と食物繊維の組み合わせで阻害することにより、ミネラル吸収促進組成物の代謝が妨げられ、ミネラルの消化管吸収が促進されると考えられる。
<Operation principle of the present invention>
The principle of action of the present invention is not necessarily clear, but by using fats and oils that are degraded by a lipolytic enzyme secreted in the digestive tract, “fat digested products” such as fatty acids are produced. This newly-produced “oil digestion digest”, surfactant, dietary fiber, and mineral become emulsions or micelles in the digestive tract, interacting with the small intestinal mucosa, the hydrophilic functional component of the small intestine It is considered that digestion and absorption of both the capillary absorption pathway of fur and the lymphatic absorption pathway of the small intestine similar to fats and oils are possible. The synergistic effect of the hydrophilic functional ingredient “capillary absorption of small intestine fur” and the lipophilic functional ingredient “small intestine lymphatic absorption” promotes the absorption of minerals in the gastrointestinal tract. Is thought to improve.
In addition, the functional component transporter (P-glycoprotein) present in the gastrointestinal mucosal epithelial cells is a transporter that once pumps the functional component once permeated into the small intestinal tract. It is considered that the absorption of minerals in the gastrointestinal tract is promoted by inhibiting the action of this transporter with a combination of a surfactant and dietary fiber.
Furthermore, by inhibiting the action of the intestinal metabolic enzyme of cytochrome P450 (CYP) 3A molecular species represented by CYP3A4 by the combination of fats and oils of the present invention, surfactant and dietary fiber, metabolism of the mineral absorption promoting composition Is impeded, and the gastrointestinal absorption of minerals is thought to be promoted.
本発明に使用できる界面活性剤は、モノグリセリン脂肪酸エステル、ジグリセリン脂肪酸エステル、ポリグリセリン脂肪酸エステル、ショ糖脂肪酸エステル、ソルビタン脂肪酸エステルの群から選ばれる1種類又は2種類以上の組み合わせで、その配合量は、ミネラル吸収促進組成物全体に対し重量百分率で1〜30%で好適に用いられる。さらに好ましくは1〜20%、とりわけ好ましくは2〜15%である。その中でも、モノグリセリン脂肪酸エステル、ジグリセリン脂肪酸エステルが好適に用いられる。 The surfactant that can be used in the present invention is one or a combination of two or more selected from the group of monoglycerin fatty acid ester, diglycerin fatty acid ester, polyglycerin fatty acid ester, sucrose fatty acid ester, and sorbitan fatty acid ester. The amount is suitably used at 1 to 30% by weight with respect to the whole mineral absorption promoting composition. More preferably, it is 1 to 20%, and particularly preferably 2 to 15%. Among these, monoglycerin fatty acid ester and diglycerin fatty acid ester are preferably used.
本発明に使用できる油脂は、植物性油脂、動物性油脂、加工油脂など、食用油脂であればいずれも使用することができる。本明細書においては、植物性油脂のうち、オリーブ油のように常温で液体のものを「植物油」とし、やし油などのように常温で固体のものを「植物脂」という。また、本明細書においては、動物性油脂のうち、魚油のように常温で液体のものを「動物油」とし、牛脂やラードなどのように常温で固体のものを「動物脂」という。また、加工油脂としては、植物油や動物油に水素添加して固体にする水素添加加工油脂があげられる。 Any oils and fats that can be used in the present invention can be used as long as they are edible oils and fats such as vegetable oils, animal oils, and processed oils. In the present specification, among vegetable oils and fats, those that are liquid at normal temperatures such as olive oil are referred to as “vegetable oils”, and those that are solid at normal temperatures such as coconut oil are referred to as “vegetable fats”. In the present specification, among animal fats and oils, those that are liquid at room temperature such as fish oil are referred to as “animal oil”, and those that are solid at room temperature such as beef tallow and lard are referred to as “animal fat”. Examples of the processed fats and oils include hydrogenated processed fats and oils that are hydrogenated to vegetable oils and animal oils to form solids.
本発明の油脂として、植物油、動物油などの液体状油(常温で液体)と、植物脂、動物脂、水素添加加工油脂などの固体状脂(常温で固体)を組み合わせて用いることで、ミネラル吸収促進組成物の粘度、物性を、その用途に合わせて自由自在に調整することが可能である。例えば、ソフトカプセル内容物としてミネラル吸収促進組成物を用いる場合、ミネラル吸収促進組成物の粘度を5000〜100000Pa・sに調整することが望ましいが、20〜50%の液体状油(常温で液体)と2〜20%の水素添加加工油脂などの固体状脂(常温で固体)との組み合わせを、ソフトカプセル内容物としてミネラル吸収促進組成物を用いる場合の一例としてあげることができる。
本発明の油脂としての配合量は、ミネラル吸収促進組成物に対し、重量百分率で1〜80%で好適に用いられる。さらに好ましくは10〜70%、とりわけ好ましくは50〜70%である。
本発明のミネラル吸収促進組成物は、粉末状でも顆粒状でも、或いはそれを打錠して錠剤状、或いはそれをソフトカプセル、ハードカプセルに充填された状態でも良いが、どのような態様においても低容量化、ローコスト化することができる。また本発明で使用できるソフトカプセル皮膜としては、ゼラチン、可塑剤(グリセリン)、水を配合した皮膜のほか、でんぷん、カラギーナン、可塑剤(グリセリン)、金属塩、水を配合した植物性皮膜も使用することができる。
As oils and fats of the present invention, mineral oil is absorbed by combining liquid oils (liquid at room temperature) such as vegetable oils and animal oils with solid oils (solid at room temperature) such as vegetable oils, animal fats and hydrogenated processed oils and fats. It is possible to freely adjust the viscosity and physical properties of the accelerating composition according to its use. For example, when using a mineral absorption promoting composition as the soft capsule content, it is desirable to adjust the viscosity of the mineral absorption promoting composition to 5000 to 100000 Pa · s, but 20 to 50% liquid oil (liquid at room temperature) and A combination with a solid fat (solid at room temperature) such as 2 to 20% hydrogenated processed fat or oil can be cited as an example when the mineral absorption promoting composition is used as the soft capsule content.
The blending amount of the oil and fat of the present invention is suitably used at 1 to 80% by weight with respect to the mineral absorption promoting composition. More preferably, it is 10 to 70%, and particularly preferably 50 to 70%.
The mineral absorption promoting composition of the present invention may be in the form of powder or granules, or it may be tableted into tablets, or filled in soft capsules or hard capsules. And low cost. As the soft capsule film that can be used in the present invention, in addition to a film containing gelatin, a plasticizer (glycerin), and water, a vegetable film containing starch, carrageenan, plasticizer (glycerin), metal salt, and water is also used. be able to.
また、本発明に使用できる液体状油(常温で液体)としては、コーン油、大豆油、サラダ油、ごま油、菜種油、こめ油、糠油、椿油、サフラワー油、パーム油、綿実油、ひまわり油、オリーブオイル、ピーナッツオイル、アーモンドオイル、アボガドオイル、ヘーゼルナッツオイル、ウオルナッツオイル、グレープシードオイル、マスタードオイル、レタス油、シソ油、あまに油、ひまし油、桐油などの植物油、または、鯨油、鮫油、肝油などの魚油の群から選ばれる1種類又は2種類以上の組み合わせを例として挙げることができるが、これらに限定されるものではない。本発明に使用できる液体状油(常温で液体)の配合量は、期待する効果など考慮して適宜決定すれば良いが、ミネラル吸収促進組成物に対し、重量百分率で1〜80%で好適に用いられる。さらに好ましくは10〜70%、とりわけ好ましくは40〜60%である。 The liquid oil (liquid at room temperature) that can be used in the present invention includes corn oil, soybean oil, salad oil, sesame oil, rapeseed oil, rice bran oil, koji oil, koji oil, safflower oil, palm oil, cottonseed oil, sunflower oil, olive Oil, peanut oil, almond oil, avocado oil, hazelnut oil, walnut oil, grape seed oil, mustard oil, lettuce oil, perilla oil, linseed oil, castor oil, paulownia oil, etc., or whale oil, coconut oil, liver oil One or two or more combinations selected from a group of fish oils such as, for example, can be mentioned as examples, but are not limited thereto. The blending amount of the liquid oil (liquid at normal temperature) that can be used in the present invention may be appropriately determined in consideration of the expected effect and the like, but is preferably 1 to 80% by weight percentage with respect to the mineral absorption promoting composition. Used. More preferably, it is 10 to 70%, and particularly preferably 40 to 60%.
また、本発明に使用できる固体状脂(常温で固体)は、植物由来水素添加加工油脂、動物由来水素添加加工油脂などの水素添加加工油脂や、カカオバター、パーム油などの植物脂や、ラード(豚脂)、ヘット(牛脂)、鶏脂、兎脂、羊脂、馬脂、乳脂など動物脂、からなる群から選ばれる1種類又は2種類以上の組み合わせを例として挙げることができるが、これらに限定されるものではない。本発明に使用できる固体状脂(常温で固体)の配合量は、期待する効果やミネラル吸収促進組成物の剤型、用途に応じた物性などを考慮して適宜決定すれば良いが、ミネラル吸収促進組成物に対し、重量百分率で1〜20%で好適に用いられる。さらに好ましくは1〜15%、とりわけ好ましくは2〜10%である。本発明における植物由来水素添加加工油脂としては、硬化油、マーガリン、ショートニングオイルなどあげられ、食用油脂に水素添加または部分的に水素添加したものいずれも使用することができるが、そのなかでも硬化油が好適に用いられる。また本発明における動物由来水素添加加工油脂としては、ラードなどがあげられ、食用油脂に水素添加または部分的に水素添加したものいずれも使用することができる。 Solid fats (solid at room temperature) that can be used in the present invention include hydrogenated processed fats and oils such as plant-derived hydrogenated processed fats and fats, animal-derived hydrogenated processed fats and oils, vegetable fats such as cocoa butter and palm oil, lard Examples include 1 type or 2 or more types of combinations selected from the group consisting of (tallow fat), het (beef tallow), chicken fat, rosin, sheep fat, horse fat, milk fat and other animal fats. It is not limited to these. The amount of solid fat (solid at room temperature) that can be used in the present invention may be appropriately determined in consideration of the expected effect, the dosage form of the mineral absorption promoting composition, the physical properties according to the use, etc. It is suitably used at 1 to 20% by weight percentage with respect to the accelerating composition. More preferably, it is 1 to 15%, and particularly preferably 2 to 10%. Examples of the plant-derived hydrogenated processed fats and oils in the present invention include hardened oil, margarine, shortening oil, and the like, and edible fats and oils that are either hydrogenated or partially hydrogenated can be used. Are preferably used. Moreover, lard etc. are mention | raise | lifted as an animal-derived hydrogenated processed oil and fat in this invention, What hydrogenated or partially hydrogenated edible oil and fat can be used.
食物繊維の定義は、人間の消化酵素で消化されない食物中のすべての成分(難消化性成分の総体)である。体の構成成分やエネルギーとなることはないが、5大栄養素に続く第6の栄養素としてその有用性が見直され、排泄の促進、(有害)ミネラル排出、血中コレステロールの抑制、悪玉菌の増殖抑制、急激な血糖値上昇抑制の作用などがあり、糖尿病、高脂血症、肥満や高血圧症などの代謝性疾患に有用と考えられ、さらに大腸がんの予防が期待され、腸内環境を整えるためにも必要な栄養素となっている。 The definition of dietary fiber is all ingredients in food that are not digested by human digestive enzymes (the total of indigestible ingredients). Although it does not become a component or energy of the body, its usefulness is reviewed as the sixth nutrient following the five major nutrients, promotion of excretion, (harmful) mineral excretion, suppression of blood cholesterol, growth of bad bacteria It is effective for metabolic diseases such as diabetes, hyperlipidemia, obesity and hypertension, and is expected to prevent colorectal cancer. It is a necessary nutrient for preparation.
上述したように食物繊維は、一般的にはミネラル排出促進に有効であると考えられてきた。しかし、本発明者らは、鋭意研究を重ねた結果、ミネラル化合物を含むミネラル吸収促進組成物を調整するにあたり、ミネラル化合物と油脂と界面活性剤と食物繊維の組み合わせによって、ミネラルを効率的に血中に移行させ血中濃度曲線下面積(AUC)を上昇させることで、生物学的利用能(バイオアベイラビリティー)を向上させることを見出し、本発明を完成させた。
本発明に使用できる食物繊維は、水溶性食物繊維、または不溶性食物繊維、または水溶性食物繊維及び不溶性食物繊維の組み合わせである。食物繊維の配合量は、期待する効果など考慮して適宜決定すれば良いが、ミネラル吸収促進組成物に対し、重量百分率で1〜25%で好適に用いられる。さらに好ましくは1〜20%、とりわけ好ましくは2〜10%である。
As described above, dietary fiber has generally been considered effective in promoting mineral excretion. However, as a result of intensive studies, the present inventors have clarified that minerals can be efficiently removed by combining mineral compounds, fats and oils, surfactants, and dietary fibers in preparing a mineral absorption promoting composition containing mineral compounds. The present invention was completed by finding that bioavailability (bioavailability) is improved by increasing the area under the blood concentration curve (AUC) by shifting to the inside.
The dietary fiber that can be used in the present invention is water-soluble dietary fiber, or insoluble dietary fiber, or a combination of water-soluble dietary fiber and insoluble dietary fiber. The blending amount of the dietary fiber may be appropriately determined in consideration of the expected effect and the like, but is preferably used at 1 to 25% by weight with respect to the mineral absorption promoting composition. More preferably, it is 1 to 20%, and particularly preferably 2 to 10%.
本発明に使用できる水溶性食物繊維は、難消化性デキストリン、ポリデキストロース、アルギン酸、低分子化アルギン酸ナトリウム、ガラクトマンナン、グルコマンナン、水溶性ペクチン、フコイダン、グアガム、グアガム分解物、水溶性リグニン、コンドロイチンの群から選ばれる1種類又は2種類以上の組み合わせである。その中でも、難消化性デキストリン、ポリデキストロースが好適に用いられる。
本発明における食物繊維として、難消化性デキストリン、ポリデキストロースなどの水溶性食物繊維を用いてミネラル吸収促進組成物を調整することで、ミネラルを効率的に血中に移行させ血中濃度曲線下面積(AUC)を上昇させるだけでなく、血中最高濃度到達時間(Tmax)を速めることも可能である。
また、本発明に使用できる不溶性食物繊維は、セルロース、ふすま、ヘミセルロース、不溶性ペクチン、不溶性リグニン、グルカン、イヌリン、カラギーナン、アガロース、キチン、キトサンの群から選ばれる1種類又は2種類以上の組み合わせである。
Water-soluble dietary fiber that can be used in the present invention is resistant to dextrin, polydextrose, alginic acid, low molecular weight sodium alginate, galactomannan, glucomannan, water-soluble pectin, fucoidan, guar gum, guar gum degradation product, water-soluble lignin, chondroitin One type or a combination of two or more types selected from the group. Among these, indigestible dextrin and polydextrose are preferably used.
By adjusting the mineral absorption promoting composition using water-soluble dietary fiber such as indigestible dextrin and polydextrose as dietary fiber in the present invention, the mineral is efficiently transferred into the blood and the area under the blood concentration curve It is possible not only to increase (AUC) but also to accelerate the time to reach the maximum blood concentration (Tmax).
The insoluble dietary fiber that can be used in the present invention is one or a combination of two or more selected from the group consisting of cellulose, bran, hemicellulose, insoluble pectin, insoluble lignin, glucan, inulin, carrageenan, agarose, chitin, and chitosan. .
人体の元素別割合は、炭素、水素、酸素、窒素 の4つで、全体の96%を占めており、残りの4%をミネラル(無機質)が占めている。体内でのミネラルの量は微量であるが、生命の維持には必要不可欠な栄養素である。ミネラルには、骨や歯の成分、血液やホルモン、酵素の構成成分、そして体のバランスを整えたり強化したりする成分としての役割がある。厚生労働省によって、亜鉛・カリウム・カルシウム・クロム・セレン・鉄・銅・ナトリウム・マグネシウム・マンガン・ヨウ素・リンの12種類がミネラルとして示されているが、その他の無機質も加えるともっと多くの数になる。
本発明におけるミネラル化合物のミネラルとして使用できるものは、生体内で必要とされるカルシウム、マグネシウム、鉄、亜鉛、カリウム、クロム、セレン、銅、ナトリウム、マンガン、ヨウ素、リン、モリブデン、コバルト、バナジウム、などからなる群から選ばれる1種類又は2種類以上の組み合わせである。
本発明におけるミネラル化合物として使用できるものは、生体内で必要とされるカルシウム化合物、マグネシウム化合物、鉄化合物、亜鉛化合物、カリウム化合物、クロム化合物、セレン化合物、銅化合物、ナトリウム化合物、マンガン化合物、ヨウ素化合物、リン化合物、モリブデン化合物、コバルト化合物、バナジウム化合物、などからなる群から選ばれる1種類又は2種類以上の組み合わせである。
The proportion of the human body by element is carbon, hydrogen, oxygen, and nitrogen, accounting for 96% of the total, and the remaining 4% is mineral (inorganic). Although the amount of minerals in the body is very small, it is an essential nutrient for the maintenance of life. Minerals play a role as bone and tooth components, blood and hormones, enzyme components, and components that balance and strengthen the body. According to the Ministry of Health, Labor and Welfare, 12 types of zinc, potassium, calcium, chromium, selenium, iron, copper, sodium, magnesium, manganese, iodine, and phosphorus are listed as minerals. Become.
What can be used as the mineral of the mineral compound in the present invention is calcium, magnesium, iron, zinc, potassium, chromium, selenium, copper, sodium, manganese, iodine, phosphorus, molybdenum, cobalt, vanadium, One type or a combination of two or more types selected from the group consisting of and the like.
What can be used as a mineral compound in the present invention is a calcium compound, magnesium compound, iron compound, zinc compound, potassium compound, chromium compound, selenium compound, copper compound, sodium compound, manganese compound, iodine compound required in vivo. , A phosphorus compound, a molybdenum compound, a cobalt compound, a vanadium compound, and the like.
また、本発明におけるミネラル吸収促進組成物に、油脂と、界面活性剤と、食物繊維と、共に含有せしめるミネラル化合物としては、生体に吸収可能な形態の前記ミネラルの化合物、これらのミネラルを高含有する天然物、或いは、これらのミネラルを含有する加工品をいう。具体的には、例えば、カルシウム化合物としては、炭酸カルシウム、塩化カルシウム、クエン酸カルシウム、グルコン酸カルシウム、グリセロリン酸カルシウム、乳酸カルシウム、オルトリン酸カルシウム、水酸化カルシウム、酸化カルシウムなどや、乳清カルシウム、苦汁、卵殻カルシウム、牛骨カルシウム、魚骨粉、サンゴ末、貝殻、ドロマイトや、それらの加工品を挙げることができる。 In addition, the mineral absorption promoting composition according to the present invention, as a mineral compound that contains oils and fats, surfactants, and dietary fiber, the mineral compound in a form that can be absorbed by the living body, and a high content of these minerals. Natural product or processed product containing these minerals. Specifically, for example, calcium compounds include calcium carbonate, calcium chloride, calcium citrate, calcium gluconate, calcium glycerophosphate, calcium lactate, calcium orthophosphate, calcium hydroxide, calcium oxide, whey calcium, bitter juice, Egg shell calcium, beef bone calcium, fish bone powder, coral powder, shells, dolomite, and processed products thereof can be mentioned.
マグネシウム化合物としては、炭酸マグネシウム、塩化マグネシウム、硫酸マグネシウム、酢酸マグネシウム、グルコン酸マグルシウム、グリセロリン酸マグネウム、乳酸マグネシウム、オルトリン酸マグネシウム、水酸化マグネシウム、酸化マグネシウムなどや、マグネシウムを高含有するカカオ豆、アーモンド、大豆、ピーナッツ、苦汁、米糠、ひじき、昆布などの海草類やこれらの加工品を挙げることができる。 Magnesium compounds include magnesium carbonate, magnesium chloride, magnesium sulfate, magnesium acetate, magnesium gluconate, magnesium glycerophosphate, magnesium lactate, magnesium orthophosphate, magnesium hydroxide, magnesium oxide, cocoa beans and almonds with high magnesium content. , Seaweeds such as soybeans, peanuts, bitter juice, rice bran, hijiki, kelp, and processed products thereof.
鉄化合物としては、クエン酸第一鉄、炭酸第一鉄、クエン酸第二鉄アンモニウム、重炭酸カリウムグルコン酸第一鉄、乳酸第一鉄、硫酸第一鉄、フマル酸第一鉄、リン酸鉄ナトリウム(二リン酸第二鉄)、一リン酸第二鉄(ピロリン酸第二鉄)、含糖酸化鉄、元素鉄などを挙げることができる。 Ferrous citrate, ferrous carbonate, ferric ammonium citrate, potassium bicarbonate ferrous gluconate, ferrous lactate, ferrous sulfate, ferrous fumarate, phosphoric acid Examples thereof include sodium iron (ferric diphosphate), ferric monophosphate (ferric pyrophosphate), sugar-containing iron oxide, and elemental iron.
亜鉛化合物としては、酢酸亜鉛、塩化亜鉛、クエン酸亜鉛、グルコン酸亜鉛、乳酸亜鉛、酸化亜鉛、炭酸亜鉛、硫酸亜鉛などを挙げることができる。 Examples of the zinc compound include zinc acetate, zinc chloride, zinc citrate, zinc gluconate, zinc lactate, zinc oxide, zinc carbonate, and zinc sulfate.
カリウム化合物としては、オルトリン酸カリウム、クエン酸カリウム、塩化カリウム、炭酸カリウム、グルコン酸カリウム、グリセロリン酸カリウム、乳酸カリウム、水酸化カリウムなどを挙げることができる。 Examples of the potassium compound include potassium orthophosphate, potassium citrate, potassium chloride, potassium carbonate, potassium gluconate, potassium glycerophosphate, potassium lactate, and potassium hydroxide.
クロム化合物としては、3価クロム化合物などを挙げることができる。 Examples of the chromium compound include trivalent chromium compounds.
セレン化合物としては、セレン酸ナトリウム、亜セレン酸水素ナトリウム、亜セレン酸ナトリウムなどを挙げることができる。 Examples of the selenium compound include sodium selenate, sodium hydrogen selenite, sodium selenite and the like.
銅化合物としては、炭酸第二銅、クエン酸第二銅、グルコン酸第二銅、硫酸第二銅、リジン−銅複合体などを挙げることができる。 Examples of the copper compound include cupric carbonate, cupric citrate, cupric gluconate, cupric sulfate, and lysine-copper complex.
ナトリウム合物としては、塩化ナトリウム、リン酸三ナトリウム、炭酸ナトリウムなどを挙げることができる。 Examples of sodium compounds include sodium chloride, trisodium phosphate, sodium carbonate and the like.
マンガン化合物としては、炭酸マンガン、硫酸マンガンなどを挙げることができる。 Examples of manganese compounds include manganese carbonate and manganese sulfate.
リン化合物としては、リン酸カルシウム、リン酸マグネシウム、リン酸ナトリウム、リン酸などを挙げることができる。 Examples of the phosphorus compound include calcium phosphate, magnesium phosphate, sodium phosphate, and phosphoric acid.
ヨウ素化合物としては、ヨウ化ナトリウム、ヨウ素酸ナトリウム、ヨウ化カリウム、ヨウ素酸カリウムなどを挙げることができる。 Examples of the iodine compound include sodium iodide, sodium iodate, potassium iodide, and potassium iodate.
なお、鉄、亜鉛、カリウム、クロム、セレン、銅、ナトリウム、マンガン、ヨウ素、リン、モリブデン、コバルト、バナジウム、については、それらを高含有する天然物或いは加工品を、具体的に例示はしていないが、それらも、当然、本発明のミネラル吸収促進組成物にミネラル化合物として有利に配合することができる。また、これらのミネラル化合物は、その1種又は2種以上を、本発明のミネラル吸収促進組成物の使用目的により、適宜配合することができ、その組み合わせは、同じ種類のミネラル化合物を2種以上組み合わせることも、及び/又は、異なる複数の種類のミネラル化合物を2種以上組み合わせることも、随意である。 As for iron, zinc, potassium, chromium, selenium, copper, sodium, manganese, iodine, phosphorus, molybdenum, cobalt, and vanadium, specific examples of natural products or processed products that contain a high content thereof are given. However, naturally, they can be advantageously blended in the mineral absorption promoting composition of the present invention as a mineral compound. Moreover, these mineral compounds can mix | blend the 1 type (s) or 2 or more types suitably according to the intended purpose of the mineral absorption promotion composition of this invention, and the combination is 2 or more types of the same kind of mineral compounds. It is also optional to combine and / or combine two or more different types of mineral compounds.
本発明におけるミネラル吸収促進組成物のミネラル化合物の配合量は、期待する効果など考慮して適宜決定すれば良いが、ミネラル吸収促進組成物全体に対し、重量百分率で0.5〜60%で好適に用いられる。さらに好ましくは5〜50%、とりわけ好ましくは10〜40%である。 The blending amount of the mineral compound of the mineral absorption promoting composition in the present invention may be appropriately determined in consideration of the expected effect and the like, but it is preferably 0.5 to 60% by weight percentage with respect to the entire mineral absorption promoting composition. Used for. More preferably, it is 5 to 50%, and particularly preferably 10 to 40%.
本発明において、ミネラル吸収促進組成物として、ミネラル化合物の他、更にミネラル化合物以外の親水性機能性成分、親油性機能性成分の群から選ばれる1種類又は2種類以上の組み合わせを含有していても、本発明の作用効果を阻害するものではなく、ミネラル以外の親水性機能性成分、親油性機能性成分などもミネラルと同様に効率的に血中に移行させ血中濃度曲線下面積(AUC)を上昇させることで、生物学的利用能(バイオアベイラビリティー)を向上させることが可能である。 In the present invention, the mineral absorption promoting composition contains one or more combinations selected from the group of hydrophilic functional components other than mineral compounds and lipophilic functional components in addition to mineral compounds. However, it does not inhibit the action and effect of the present invention, and hydrophilic functional components other than minerals, lipophilic functional components, etc. are transferred to the blood efficiently in the same manner as minerals, and the area under the blood concentration curve (AUC) ) Is increased, it is possible to improve bioavailability.
本発明に使用できる親水性機能性成分としては、ビタミンB群(ビタミンB1、ビタミンB2、ナイアシン、ビタミンB6、ビタミンB12、パントテン酸、葉酸、ビオチン)とビタミンCからなる水溶性ビタミンや、グルコサミン塩酸塩、ルチン、タウリン、米酢、米黒酢、玄米酢、玄米黒酢、大麦黒酢、ハトムギ酢、小麦酢、りんご酢、ぶどう酢、柿酢、梅酢、トマト酢、もろみ酢、水溶性オリゴ糖、水溶性デキストリン、イソフラボン、フラボノール、フラバノン、アントシアニン、フラバノール、フラボン、カテキン、タンニン、フラボノイド、クロロゲン酸、フェニルカルボン酸、エラグ酸、リグナン、クルクミン、クマリン、αリポ酸、キシリトール、大豆ペプチド、大豆イソフラボン、クエン酸、グリシン、アラニン、セリン、システイン、シスチン、メチオニン、グルタミン、アルギニン、ヒスチジン、コラーゲンペプチドなどを挙げることができるが、これらに限定されるものではなく、ありとあらゆる親水性機能性成分を使用することができる。 Hydrophilic functional ingredients that can be used in the present invention include water-soluble vitamins consisting of vitamin B group (vitamin B1, vitamin B2, niacin, vitamin B6, vitamin B12, pantothenic acid, folic acid, biotin) and vitamin C, and glucosamine hydrochloride Salt, rutin, taurine, rice vinegar, rice black vinegar, brown rice vinegar, brown rice black vinegar, barley black vinegar, wheat vinegar, wheat vinegar, apple vinegar, grape vinegar, straw vinegar, plum vinegar, tomato vinegar, moromi vinegar, water soluble oligo Sugar, water-soluble dextrin, isoflavone, flavonol, flavanone, anthocyanin, flavanol, flavone, catechin, tannin, flavonoid, chlorogenic acid, phenylcarboxylic acid, ellagic acid, lignan, curcumin, coumarin, alpha lipoic acid, xylitol, soy peptide, soybean Isoflavones, citric acid, glycine, alanine, serine, system In, cystine, methionine, glutamine, arginine, histidine, collagen peptide and the like can be mentioned, but not limited to these, and any hydrophilic functional component can be used.
本発明におけるミネラル吸収促進組成物のミネラル化合物以外の親水性機能性成分の配合量は、期待する効果など考慮して適宜決定すれば良いが、ミネラル吸収促進組成物全体に対し、重量百分率で1〜50%で好適に用いられる。さらに好ましくは5〜40%、とりわけ好ましくは10〜30%である。 The blending amount of the hydrophilic functional component other than the mineral compound of the mineral absorption promoting composition in the present invention may be appropriately determined in consideration of the expected effect and the like, but 1% by weight with respect to the entire mineral absorption promoting composition. It is suitably used at ˜50%. More preferably, it is 5 to 40%, and particularly preferably 10 to 30%.
本発明に使用できる親油性機能性成分としては、脂溶性ビタミン(ビタミンA、ビタミンD、ビタミンE、ビタミンK)、コエンザイムQ10、DHA(ドコサヘキサエン酸)、EPA(エイコサペンタエン酸)、αカロテン、βカロテン、ルテイン、リコピン、ゼアキサンチン、植物ステロール、リノール酸、リノレン酸、アラキドン酸、オレイン酸、スクワレンなどを挙げることができるが、これらに限定されるものではなく、ありとあらゆる親油性機能性成分を使用することができる。 Examples of lipophilic functional ingredients that can be used in the present invention include fat-soluble vitamins (vitamin A, vitamin D, vitamin E, vitamin K), coenzyme Q10, DHA (docosahexaenoic acid), EPA (eicosapentaenoic acid), α-carotene, β Examples include, but are not limited to, carotene, lutein, lycopene, zeaxanthin, plant sterol, linoleic acid, linolenic acid, arachidonic acid, oleic acid, squalene, and any and all lipophilic functional ingredients are used. be able to.
本発明におけるミネラル吸収促進組成物のミネラル化合物以外の親油性機能性成分の配合量は、期待する効果など考慮して適宜決定すれば良いが、ミネラル吸収促進組成物全体に対し、重量百分率で1〜50%で好適に用いられる。さらに好ましくは5〜40%、とりわけ好ましくは10〜30%である。 The blending amount of the lipophilic functional component other than the mineral compound of the mineral absorption promoting composition in the present invention may be appropriately determined in consideration of the expected effect and the like, but 1% by weight with respect to the entire mineral absorption promoting composition. It is suitably used at ˜50%. More preferably, it is 5 to 40%, and particularly preferably 10 to 30%.
本発明におけるミネラル吸収促進組成物の製造方法は、ミネラル吸収促進組成物を調整するにあたり、ミネラル化合物と、油脂と、界面活性剤と、食物繊維を、高速攪拌機または高速粉砕機を用いて攪拌処理し均一化することを特徴の1つとする。そして本発明のミネラル吸収促進組成物の製造方法における攪拌処理は、1次攪拌処理と2次攪拌処理からなり、好ましくは、1次攪拌処理として、油脂に界面活性剤を加え、温度65±5℃でホモジェッターなどの高速攪拌機を用いて徐々に回転数を上げ、2000〜8000rpmで10〜30分間攪拌して均一化する。そして、均一化した中間組成物を、温度40±10℃まで冷却し、2次攪拌処理として、均一化した中間組成物にミネラル化合物と食物繊維を加え、さらに必要に応じてミネラル化合物以外の機能性成分やpH調整剤などを加えて、温度40±10℃でホモジェッターなどの高速攪拌機を用いて徐々に回転数を上げ、2000〜8000rpmで10〜30分間攪拌して均一化する。
1次攪拌処理および2次攪拌処理の回転数は、期待する効果など考慮して適宜決定すれば良いが、2000〜8000rpmで好適に用いられる。さらに好ましくは3000〜7000rpm、とりわけ好ましくは3500〜5000rpmである。また、1次攪拌処理および2次攪拌処理各々の時間は、期待する効果など考慮して適宜決定すれば良いが、5〜50分間が好適であり、さらに好ましくは10〜40分間、とりわけ好ましくは20〜30分間である。従って、1次攪拌処理および2次攪拌処の合計時間は、期待する効果など考慮して適宜決定すれば良いが、10〜100分間が好適であり、さらに好ましくは20〜80分間、とりわけ好ましくは40〜60分間である。
本発明の攪拌処理に使用できる高速攪拌機または高速粉砕機としては、ホモジェッター、ホモミキサー、ポリトロンホモジナイザー、クレアミックス、ヒスコトロンなどを挙げることができるが、これらに限定されるものではなく、市販されている高速攪拌機または高速粉砕機であればいずれも使用することができる。
In the method for producing a mineral absorption promoting composition in the present invention, in preparing a mineral absorption promoting composition, a mineral compound, fats and oils, a surfactant, and dietary fiber are stirred using a high-speed stirrer or a high-speed pulverizer. One of the characteristics is to make it uniform. And the stirring process in the manufacturing method of the mineral absorption promotion composition of this invention consists of a primary stirring process and a secondary stirring process, Preferably, surfactant is added to fats and oils as a primary stirring process, and the temperature is 65 +/- 5. Using a high-speed stirrer such as a homo-jetter at 0 ° C., the number of revolutions is gradually increased, and the mixture is homogenized by stirring at 2000 to 8000 rpm for 10 to 30 minutes. Then, the homogenized intermediate composition is cooled to a temperature of 40 ± 10 ° C., and as a secondary stirring treatment, a mineral compound and dietary fiber are added to the homogenized intermediate composition, and functions other than the mineral compound as necessary. Sexual components, pH adjusting agents, and the like are added, and the number of revolutions is gradually increased using a high-speed stirrer such as a homojetter at a temperature of 40 ± 10 ° C., and the mixture is homogenized by stirring at 2000 to 8000 rpm for 10 to 30 minutes.
The rotational speeds of the primary stirring process and the secondary stirring process may be appropriately determined in consideration of expected effects and the like, but are preferably used at 2000 to 8000 rpm. More preferably, it is 3000-7000 rpm, Most preferably, it is 3500-5000 rpm. Further, the time of each of the primary stirring treatment and the secondary stirring treatment may be appropriately determined in consideration of the expected effect, etc., but is preferably 5 to 50 minutes, more preferably 10 to 40 minutes, particularly preferably 20-30 minutes. Therefore, the total time of the primary stirring treatment and the secondary stirring treatment may be appropriately determined in consideration of the expected effect, etc., but is preferably 10 to 100 minutes, more preferably 20 to 80 minutes, particularly preferably 40-60 minutes.
Examples of the high-speed stirrer or high-speed pulverizer that can be used in the stirring treatment of the present invention include a homojetter, a homomixer, a polytron homogenizer, Claremix, and Hiscotron, but are not limited thereto and are commercially available. Any high-speed stirrer or high-speed pulverizer can be used.
本発明におけるミネラル吸収促進組成物には、ミネラル化合物と、油脂と、界面活性剤と、食物繊維と、共にpH調整剤を含有させることがより好ましい。本発明に使用できるpH調整剤としては、クエン酸、酢酸、リンゴ酸、コハク酸、グルコン酸などの有機酸、またはクエン酸ナトリウム、クエン酸第一鉄ナトリウム、コハク酸ナトリウム、グルコン酸ナトリウムなどの有機酸塩、またはリン酸水素二ナトリウム、リン酸二水素ナトリウムなどの無機金属塩を挙げることができるが、これらに限定されるものではない。 More preferably, the mineral absorption promoting composition of the present invention contains a mineral compound, an oil and fat, a surfactant, and a dietary fiber together with a pH adjuster. Examples of pH adjusting agents that can be used in the present invention include organic acids such as citric acid, acetic acid, malic acid, succinic acid, and gluconic acid, or sodium citrate, sodium ferrous citrate, sodium succinate, sodium gluconate, and the like. Examples of the organic acid salt include inorganic metal salts such as disodium hydrogen phosphate and sodium dihydrogen phosphate, but are not limited thereto.
本発明におけるミネラル吸収促進組成物のpH調整剤の配合量は、期待する効果など考慮して適宜決定すれば良いが、ミネラル吸収促進組成物全体に対し、重量百分率で0.1〜10%で好適に用いられる。さらに好ましくは0.2〜3%、とりわけ好ましくは0.3〜1%である。 The blending amount of the pH adjuster of the mineral absorption promoting composition in the present invention may be appropriately determined in consideration of the expected effects and the like, but is 0.1 to 10% by weight with respect to the entire mineral absorption promoting composition. Preferably used. More preferably, it is 0.2 to 3%, and particularly preferably 0.3 to 1%.
以下の実施例によって本発明をより詳細に説明するが、本発明はこれらの実施例に限定されるものではない。実施例に先立ち、各実施例に用いた試験方法について説明する。 The present invention will be described in more detail by the following examples, but the present invention is not limited to these examples. Prior to the examples, the test methods used in the examples will be described.
<実験群及び試料、その調整>
以下に示す成分組成にて、1 本発明品群(ミネラル吸収促進処方群)、2 対照群A(乳化促進処方群)、3 対照群B(粉末処方群)の試料を調製した。 以下1〜3群の配合処方には、いずれも同一量のカルシウムを含有しており、1 本発明品群(ミネラル吸収促進処方群)は、界面活性剤と水溶性食物繊維を含むオイル製剤としている。2 対照群A(乳化促進処方群)は、乳化促進のために界面活性剤(乳化剤)を配合して水溶化処方とした。3 対照群B(粉末処方群)は、カルシウムを含有するミネラル化合物を水で溶いて懸濁物とした。
また、ミネラル化合物としてドロマイトを用いた。ドロマイトは炭酸マグネシウムカルシウム(CaMg(CO3)2)でカルシウムとマグネシウムを2:1の割合で含有した天然のミネラル素材であり、人が栄養素として摂取する場合に、理想的なカルシウム、マグネシウム配合バランスであることが知られている。また、その含有バランスによって単体でカルシウムやマグネシウムを摂取する場合より、吸収性に富んでいると言われている。本実施例では、このドロマイトとして株式会社エヌ・シー・コーポレーション製の商品名「ドロマイトWH」を用いた。
<Experimental group and sample, preparation thereof>
Samples of 1 invention product group (mineral absorption promotion prescription group), 2 control group A (emulsification promotion prescription group), and 3 control group B (powder prescription group) were prepared with the component composition shown below. 1 to 3 groups contain the same amount of calcium. 1 The product group of the present invention (mineral absorption promotion formulation group) is an oil formulation containing a surfactant and water-soluble dietary fiber. Yes. 2 Control group A (emulsification promoting formulation group) was formulated as a water-solubilized formulation by blending a surfactant (emulsifier) to promote emulsification. 3 Control group B (powder formulation group) was prepared by dissolving a mineral compound containing calcium with water.
Moreover, dolomite was used as a mineral compound. Dolomite is a natural mineral material containing calcium and magnesium in a ratio of 2: 1 with calcium calcium carbonate (CaMg (CO3) 2). When humans take it as a nutrient, it has an ideal balance of calcium and magnesium. It is known that there is. Moreover, it is said that it is rich in absorptivity compared with the case where calcium or magnesium is ingested alone due to its balance. In this example, the trade name “Dolomite WH” manufactured by NC Corporation was used as the dolomite.
1 本発明品群(ミネラル吸収促進処方群)
ドロマイト 34.18重量%(10.254g)
クエン酸第一鉄ナトリウム 0.82重量% (0.246g)
グリセリン脂肪酸エステル 15.00重量% (4.500g)
水溶性食物繊維 5.00重量% (1.500g)
なたね硬化油(固体状脂) 5.00重量% (1.500g)
オリーブオイル(液体状油) 40.00重量%(12.000g)
100.00重量%(30.000g)
上記の1 本発明に係るミネラル吸収促進処方で、1次攪拌処理として、なたね硬化油(固体状脂)とオリーブオイル(液体状油)にグリセリン脂肪酸エステルを加え、温度65±5℃でホモジェッター(高速攪拌機)を用いて徐々に回転数を上げ、4000rpmで20分間攪拌して均一化した。そして、均一化した中間組成物を、温度40±10℃まで冷却し、2次攪拌処理として、均一化した中間組成物にドロマイト、クエン酸第一鉄ナトリウム、水溶性食物繊維(水溶性難消化性デキストリン)を加えて、温度40±10℃でホモジェッター(高速攪拌機)を用いて徐々に回転数を上げ、4000rpmで20分間攪拌して均一化することで、1 本発明品群(ミネラル吸収促進処方群)であるミネラル吸収促進組成物を得た。そのミネラル吸収促進組成物を強制経口投与で用いた。そのミネラル吸収促進組成物には、カルシウムが34.18mg/ml、マグネシウムが17.10mg/ml、鉄が0.42mg/ml含まれている。
なお、グリセリン脂肪酸エステルは、理研ビタミン社製のHLB 16(商品名 ポエムJ−0021) とHLB 7.4(商品名 ポエムDO−100V)の2種類を用い、HLB 16(商品名 ポエムJ−0021) を5.00重量%使用し、HLB 7.4(商品名 ポエムDO−100V)を10.00重量%使用し、合計で15.00重量%になるようにした。
1 Invention product group (mineral absorption promotion prescription group)
Dolomite 34.18% by weight (10.254 g)
Sodium ferrous citrate 0.82% by weight (0.246g)
Glycerin fatty acid ester 15.00% by weight (4.500 g)
Water-soluble dietary fiber 5.00% by weight (1.500 g)
Seed hardened oil (solid fat) 5.00 wt% (1.500 g)
Olive oil (liquid oil) 40.00 wt% (12.000 g)
100.00 wt% (30.000 g)
In the mineral absorption promotion formulation according to the present invention, glycerin fatty acid ester is added to rapeseed hydrogenated oil (solid fat) and olive oil (liquid oil) as a primary stirring treatment and homogenized at a temperature of 65 ± 5 ° C. Using a jetter (high-speed stirrer), the number of revolutions was gradually increased, and the mixture was homogenized by stirring at 4000 rpm for 20 minutes. Then, the homogenized intermediate composition is cooled to a temperature of 40 ± 10 ° C., and as a secondary stirring treatment, the homogenized intermediate composition is mixed with dolomite, sodium ferrous citrate, water-soluble dietary fiber (water-soluble indigestible 1 d product group (mineral absorption) by adding a dextrin) and gradually increasing the number of revolutions using a homojetter (high speed stirrer) at a temperature of 40 ± 10 ° C. A mineral absorption promoting composition which is an accelerated prescription group) was obtained. The mineral absorption promoting composition was used by oral gavage. The mineral absorption promoting composition contains 34.18 mg / ml calcium, 17.10 mg / ml magnesium, and 0.42 mg / ml iron.
The glycerin fatty acid ester is HLB 16 (trade name Poem J-0021) and HLB 7.4 (trade name Poem DO-100V) manufactured by Riken Vitamin Co., Ltd., and HLB 16 (trade name Poem J-0021). ) Was used at 5.00 wt%, HLB 7.4 (trade name Poem DO-100V) was used at 10.00 wt%, so that the total amount was 15.00 wt%.
2 対照群A(乳化促進処方群)
ドロマイト 34.18重量%(10.254g)
クエン酸第一鉄ナトリウム 0.82重量% (0.246g)
グリセリン脂肪酸エステル 20.00重量% (6.000g)
水 45.00重量%(13.500g)
100.00重量%(30.000g)
上記の2 対照群A(乳化促進処方群)に係る配合処方で、温度40±10℃で、ホモジェッター(高速攪拌機)を用いて徐々に回転数を上げ、4000rpmで40分間攪拌して均一化することでミネラル化合物含有組成物を調整した。そのミネラル化合物含有組成物を強制経口投与で用いた。そのミネラル化合物含有組成物(2 対照群A(乳化促進処方群))には、1 本発明品群(ミネラル吸収促進処方群)と同量のカルシウム、マグネシウム、鉄が含まれている。
なお、グリセリン脂肪酸エステルは、理研ビタミン社製のHLB 16(商品名 ポエムJ−0021) とHLB 7.4(商品名 ポエムDO−100V)の2種類を用い、HLB 16(商品名 ポエムJ−0021) を15.00重量%使用し、HLB 7.4(商品名 ポエムDO−100V)を5.00重量%使用し、合計で20.00重量%になるようにした。
2 Control group A (emulsification promotion prescription group)
Dolomite 34.18% by weight (10.254 g)
Sodium ferrous citrate 0.82% by weight (0.246g)
Glycerin fatty acid ester 20.00 wt% (6.0000 g)
Water 45.00% by weight (13.500 g)
100.00 wt% (30.000 g)
In the formulation according to 2 Control Group A (emulsification promotion formulation group), at a temperature of 40 ± 10 ° C, gradually increase the number of rotations using a homojetter (high speed stirrer) and stir at 4000 rpm for 40 minutes to homogenize. The mineral compound containing composition was adjusted by doing. The mineral compound-containing composition was used by oral gavage. The mineral compound-containing composition (2 control group A (emulsification promotion prescription group)) contains the same amount of calcium, magnesium, and iron as the one invention group (mineral absorption promotion prescription group).
The glycerin fatty acid ester is HLB 16 (trade name Poem J-0021) and HLB 7.4 (trade name Poem DO-100V) manufactured by Riken Vitamin Co., Ltd., and HLB 16 (trade name Poem J-0021). ) Was used at 15.00% by weight and HLB 7.4 (trade name Poem DO-100V) was used at 5.00% by weight so that the total amount was 20.00% by weight.
3 対照群B(粉末処方群)
ドロマイト 34.18重量% (10.254g)
クエン酸第一鉄ナトリウム 0.82重量% (0.246g)
水 65.00重量% (19.500g)
100.00重量% (30.000g)
上記の3 対照群B(粉末処方群)に係るミネラル化合物含有組成物として、34.18重量%(10.254g)のドロマイトと0.82重量% (0.246g)のクエン酸第一鉄ナトリウム、65.00重量% (19.500g)の脱イオン水を、温度40±10℃で、ホモジェッター(高速攪拌機)を用いて徐々に回転数を上げ、4000rpmで40分間攪拌して混合した。そのミネラル化合物含有組成物を強制経口投与で用いた。そのミネラル化合物含有組成物(3 対照群B(粉末処方群))にも、1 本発明品群(ミネラル吸収促進処方群)、2 対照群A(乳化促進処方群)と同量のカルシウム、マグネシウム、鉄が含まれている。
3 Control group B (powder formulation group)
Dolomite 34.18% by weight (10.254g)
Sodium ferrous citrate 0.82% by weight (0.246g)
Water 65.00% by weight (19.500g)
100.00 wt% (30.000 g)
As a mineral compound-containing composition according to the above-mentioned 3 control group B (powder formulation group), 34.18 wt% (10.254 g) dolomite and 0.82 wt% (0.246 g) sodium ferrous citrate 65.00% by weight (19.500 g) of deionized water was mixed at a temperature of 40 ± 10 ° C. using a homojetter (high-speed stirrer), gradually increasing the number of revolutions and stirring at 4000 rpm for 40 minutes. The mineral compound-containing composition was used by oral gavage. The mineral compound-containing composition (3 control group B (powder formulation group)) also contains the same amount of calcium and magnesium as 1 product group (mineral absorption promotion formulation group) and 2 control group A (emulsification promotion formulation group). Contains iron.
<動物群及び試料の投与方法>
本実施例で用いた動物群は、雄Sprague-Dawley系ラット、6週齢、体重が200〜235gであり、大連医科大学試験動物センターより提供を受けた。ラットは動物実験室で7日間検疫、馴化すると同時に健康状況を観察した。ラット数は各ゲージに6匹ずつで、ゲージの中に柔らかい滅菌済みの木屑を敷いた。動物実験室の温度は23〜25℃、相対湿度は50〜60%に維持した。換気回数は約12回/時間、照明は明を12時間、暗を12時間とした。動物飼料は棒状の乾燥した基礎飼料を、飲水は水道水を与え自由摂取とした。
ラットを体重によってランダムに群分けして、それぞれ、1 本発明品群(ミネラル吸収促進処方群)、2 対照群A(乳化促進処方群)、3 対照群B(粉末処方群)とし、1群につき36匹とした。群ごとのラットを生物サンプルの採集時間によってさらに、6つの小群に分けて、1群について6匹とした。ラットを一夜(約16時間)空腹にしてから、被験物質を強制経口投与し、投与用量は4ml/kg b.w.とした。カルシウムの用量は、136.7mg/kg b.w.であり、この用量は日本厚生労働省が推奨する成人用量の10倍に相当する。
<Animal group and sample administration method>
The animal group used in this example was a male Sprague-Dawley rat, 6 weeks old, weighing 200-235 g, and was provided by the Dalian Medical University Test Animal Center. Rats were quarantined and acclimatized for 7 days in an animal laboratory and observed health status. There were 6 rats in each gauge, and soft sterilized wood chips were laid in the gauge. The animal laboratory temperature was maintained at 23-25 ° C. and relative humidity at 50-60%. The number of ventilations was about 12 times / hour, the lighting was 12 hours for light and 12 hours for darkness. Animal feed was a rod-shaped dry basic feed, and drinking water was tap water to allow free consumption.
Rats are randomly divided into groups according to body weight, 1 group of the present invention (mineral absorption promotion formulation group), 2 control group A (emulsification promotion formulation group), 3 control group B (powder formulation group), 1 group, respectively. 36 animals per animal. The rats in each group were further divided into 6 subgroups according to the collection time of the biological sample, so that 6 rats per group. After the rats were fasted overnight (about 16 hours), the test substance was orally administered by gavage, and the dose was 4 ml / kg bw. The calcium dose is 136.7 mg / kg bw, which corresponds to 10 times the adult dose recommended by the Japanese Ministry of Health, Labor and Welfare.
<血中カルシウム濃度の測定 及び カルシウム吸収動態の調査解析>
ラットに被験物質を投与する直前(0時間)、及び投与後1時間、2時間、4時間、8時間及び12時間に血液と肝臓組織を採集し、血中カルシウム濃度の測定及びカルシウム吸収動態の調査解析を行った。
<Measurement of blood calcium concentration and investigation of calcium absorption dynamics>
Blood and liver tissues were collected immediately before administration of the test substance to rats (0 hour) and at 1 hour, 2 hours, 4 hours, 8 hours and 12 hours after administration, and blood calcium concentration measurement and calcium absorption kinetics were measured. Survey analysis was conducted.
<実験結果>
血中カルシウム濃度を測定し、カルシウム吸収動態の調査解析結果を表1に示し、血中カルシウム濃度の経時変化を図1に示す。
<Experimental result>
The blood calcium concentration was measured, the results of the investigation and analysis of the calcium absorption kinetics are shown in Table 1, and the change over time in the blood calcium concentration is shown in FIG.
表1及び図1より、1 本発明品群(ミネラル吸収促進処方群)のラットに対するカルシウムの吸収は、2 対照群A(乳化促進処方群)、3対照群B(粉末処方群)と比較し有意に吸収性が優れていた。1 本発明品群(ミネラル吸収促進処方群)のラットに対するカルシウムの血中濃度曲線下面積(AUC)は、3 対照群B(粉末処方群)と比較し約137%に増加し、1 本発明品群(ミネラル吸収促進処方群)の血中最高濃度(Cmax)は、3 対照群B(粉末処方群)と比較し約178%に増加した。
また、1 本発明品群(ミネラル吸収促進処方群)のラットに対するカルシウムの血中濃度曲線下面積(AUC)を、2 対照群A(乳化促進処方群)と比較すると、約29%増加しており、1 本発明品群(ミネラル吸収促進処方群)の血中最高濃度(Cmax)を、2 対照群A(乳化促進処方群)と比較すると、約65%増加した。
From Table 1 and FIG. 1, the absorption of calcium in rats of 1 product group of the present invention (mineral absorption promotion formulation group) is compared with 2 control group A (emulsification promotion formulation group) and 3 control group B (powder formulation group). The absorbency was significantly superior. 1 The area under the blood concentration curve (AUC) of calcium for rats of the product group of the present invention (mineral absorption promotion formulation group) increased to about 137% compared to 3 control group B (powder formulation group). The maximum blood concentration (Cmax) of the product group (mineral absorption promotion prescription group) increased to about 178% compared with 3 control group B (powder prescription group).
In addition, the area under the blood concentration curve (AUC) of calcium in rats of 1 invention product group (mineral absorption promotion prescription group) increased by about 29% compared to 2 control group A (emulsification promotion prescription group). The maximum blood concentration (Cmax) of 1 product group of the present invention (mineral absorption promotion prescription group) was increased by about 65% compared with 2 control group A (emulsification promotion prescription group).
1 本発明品群(ミネラル吸収促進処方群)により得られるカルシウム吸収動態の変化は、今までに知られているカルシウム吸収の知見から説明できるものではなく、一般的に知られているカルシウム吸収とは全く異なる吸収メカニズムにより、血中へのカルシウム吸収が著しく促進されているものと考えることができる。
一般的に、カルシウムの吸収促進は、牛乳に含まれるCCP(Casein Calcium Peptide:カゼインカルシウムペプチド)やビタミンDによるものと考えられている。その他にも、CCM(クエン酸リンゴ酸カルシウム)やCPP(カゼインホスホペプチド)などがカルシウムの吸収促進成分として挙げられ、それらを含む栄養機能食品や特定保健用食品なども市販されている。
しかしながら、1 本発明品群(ミネラル吸収促進処方群)において、CCP(カゼインカルシウムペプチド)やビタミンD、CCM(クエン酸リンゴ酸カルシウム)やCPP(カゼインホスホペプチド)など何れも含まれていないにも関わらず、効率よくカルシウム吸収が行われていることが、本実験結果により明確になった。これは、本発明者らによって初めて見出された事実である。
1 The change in calcium absorption kinetics obtained by the product group of the present invention (mineral absorption promotion prescription group) cannot be explained from the knowledge of calcium absorption known so far, and is generally known as calcium absorption. It can be considered that calcium absorption into the blood is remarkably accelerated by a completely different absorption mechanism.
In general, it is considered that calcium absorption is promoted by CCP (Casein Calcium Peptide) and vitamin D contained in milk. In addition, CCM (calcium citrate malate), CPP (casein phosphopeptide) and the like are listed as calcium absorption promoting components, and nutritional functional foods and foods for specified health use containing them are also commercially available.
However, in 1 product group of the present invention (mineral absorption promotion prescription group), none of CCP (casein calcium peptide), vitamin D, CCM (calcium citrate malate), CPP (casein phosphopeptide) etc. is contained. Regardless, the results of this experiment have clarified that calcium is efficiently absorbed. This is a fact first found by the present inventors.
本発明は、「医薬品」、「特定保健用食品」、「いわゆる健康食品」、「機能性食品」および食品、飲料及び菓子の分野全てにおいて利用することができる。 The present invention can be used in the fields of “pharmaceuticals”, “special health foods”, “so-called health foods”, “functional foods” and foods, beverages and confectionery.
Claims (9)
前記ミネラル吸収促進組成物を調整するにあたり、ミネラル化合物と油脂と界面活性剤のほか、更に食物繊維を組み合わせ、
これらミネラル化合物と、油脂と、界面活性剤と、食物繊維を、高速攪拌機または高速粉砕機を用いて、回転数2000〜8000rpmで10〜100分間攪拌処理し均一化することを特徴とする請求項1記載のミネラル吸収促進組成物の製造方法。 The mineral compound is any one or a combination of two or more selected from compounds of calcium, magnesium, iron, zinc, potassium, chromium, selenium, copper, sodium, manganese, iodine, phosphorus, molybdenum, cobalt, vanadium The blending amount of the mineral compound is 1 to 60% by weight based on the whole mineral absorption promoting composition,
In preparing the mineral absorption promoting composition, in addition to mineral compounds, fats and oils, surfactants, and further combining dietary fiber,
The mineral compound, fats and oils, surfactant, and dietary fiber are stirred and homogenized at a rotational speed of 2000 to 8000 rpm for 10 to 100 minutes using a high speed stirrer or a high speed grinder. A method for producing the mineral absorption promoting composition according to 1.
前記油脂が、液体状油と固体状脂の群から選ばれる1種類又は2種類以上の組み合わせで、その配合量が1〜80重量%であり、
前記食物繊維が、水溶性食物繊維、または不溶性食物繊維、または水溶性食物繊維及び不溶性食物繊維の組み合わせであり、その配合量がミネラル吸収促進組成物全体に対し、1〜20重量%であり、
前記水溶性食物繊維が、難消化性デキストリン、ポリデキストロース、アルギン酸、低分子化アルギン酸ナトリウム、ガラクトマンナン、グルコマンナン、水溶性ペクチン、フコイダン、グアガム、グアガム分解物、水溶性リグニン、コンドロイチンの群から選ばれる1種類又は2種類以上の組み合わせであり、
前記不溶性食物繊維が、セルロース、ふすま、ヘミセルロース、不溶性ペクチン、不溶性リグニン、グルカン、イヌリン、カラギーナン、アガロース、キチン、キトサンの群から選ばれる1種類又は2種類以上の組み合わせであることを特徴とする請求項1または2記載のミネラル吸収促進組成物の製造方法。 The surfactant is a monoglycerin fatty acid ester, a diglycerin fatty acid ester, a polyglycerin fatty acid ester, a sucrose fatty acid ester, or a combination of two or more sorbitan fatty acid esters, and the blending amount is mineral absorption. 1 to 30% by weight relative to the entire accelerating composition;
The fats and oils are one or a combination of two or more selected from the group of liquid oils and solid fats, and the blending amount is 1 to 80% by weight,
The dietary fiber is a water-soluble dietary fiber, or an insoluble dietary fiber, or a combination of a water-soluble dietary fiber and an insoluble dietary fiber, and the amount of the dietary fiber is 1 to 20% by weight based on the whole mineral absorption promoting composition,
The water-soluble dietary fiber is selected from the group of indigestible dextrin, polydextrose, alginic acid, low molecular weight sodium alginate, galactomannan, glucomannan, water-soluble pectin, fucoidan, guar gum, guar gum degradation product, water-soluble lignin, chondroitin One type or a combination of two or more types,
The insoluble dietary fiber is one or a combination of two or more selected from the group consisting of cellulose, bran, hemicellulose, insoluble pectin, insoluble lignin, glucan, inulin, carrageenan, agarose, chitin, and chitosan. Item 3. A method for producing a mineral absorption promoting composition according to Item 1 or 2.
前記ソフトカプセル皮膜部は、ゼラチン、可塑剤、水を配合した皮膜、または、でんぷん、カラギーナン、可塑剤、金属塩、水を配合した植物性皮膜からなり、
前記ミネラル吸収促進組成物を含むソフトカプセル内容物を調整するにあたり、請求項1、2、3、4または5記載のミネラル吸収促進組成物の製造方法によって、ミネラルの血中濃度曲線下面積(AUC)を向上させたソフトカプセル。 In the soft capsule formed by coating the capsule content containing the mineral absorption promoting composition with a soft film,
The soft capsule film part is made of a film containing gelatin, a plasticizer and water, or a vegetable film containing starch, carrageenan, plasticizer, metal salt and water,
In preparing the soft capsule content containing the mineral absorption promoting composition, the area under the blood concentration curve (AUC) of the mineral according to the method for producing a mineral absorption promoting composition according to claim 1, 2, 3, 4 or 5. Improved soft capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010176026A JP2012036112A (en) | 2010-08-05 | 2010-08-05 | Method for manufacturing product for improving bioavailability, and the product |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010176026A JP2012036112A (en) | 2010-08-05 | 2010-08-05 | Method for manufacturing product for improving bioavailability, and the product |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2012036112A true JP2012036112A (en) | 2012-02-23 |
Family
ID=45848514
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010176026A Pending JP2012036112A (en) | 2010-08-05 | 2010-08-05 | Method for manufacturing product for improving bioavailability, and the product |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2012036112A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015099102A1 (en) * | 2013-12-27 | 2015-07-02 | 富士フイルム株式会社 | Zinc-containing sleep-improving agent, non-rem sleep time-increasing agent, and sedative |
| JP2016063771A (en) * | 2014-09-24 | 2016-04-28 | 日油株式会社 | Glycerophospholipid-containing powder and health food |
| JPWO2015137357A1 (en) * | 2014-03-10 | 2017-04-06 | サラヤ株式会社 | Composition comprising sophorolipid, physiologically active substance and oil and fat, and method for producing the same |
| JP2021001142A (en) * | 2019-06-21 | 2021-01-07 | 東洋カプセル株式会社 | Hydroxytyrosol-containing soft capsule agent |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06211688A (en) * | 1991-02-16 | 1994-08-02 | Taiyo Kagaku Co Ltd | Nutriment excellent in absorbability for nitrogen source and calcium |
| JPH0833463A (en) * | 1994-07-25 | 1996-02-06 | Micro Arujie Corp Kk | Health food containing calsium as main ingredient |
| WO1998014072A1 (en) * | 1996-10-03 | 1998-04-09 | Taiyo Kagaku Co., Ltd. | Mineral composition |
| JP2001333736A (en) * | 2000-05-30 | 2001-12-04 | Taiyo Kagaku Co Ltd | Calcium composition having improved absorption efficiency |
| JP2002142720A (en) * | 2000-11-08 | 2002-05-21 | Otsuka Pharmaceut Factory Inc | Nutrition composition |
| JP2004018443A (en) * | 2002-06-14 | 2004-01-22 | Pigeon Corp | Enteric capsule |
| JP2005112753A (en) * | 2003-10-06 | 2005-04-28 | Sankyo:Kk | Soft capsule having improved bioavailability |
| JP2007191462A (en) * | 2005-12-19 | 2007-08-02 | Matsutani Chem Ind Ltd | Absorption promoter of mineral, food and fodder |
| JP2008086217A (en) * | 2006-09-29 | 2008-04-17 | Sanki Shoji Kk | healthy food |
-
2010
- 2010-08-05 JP JP2010176026A patent/JP2012036112A/en active Pending
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06211688A (en) * | 1991-02-16 | 1994-08-02 | Taiyo Kagaku Co Ltd | Nutriment excellent in absorbability for nitrogen source and calcium |
| JPH0833463A (en) * | 1994-07-25 | 1996-02-06 | Micro Arujie Corp Kk | Health food containing calsium as main ingredient |
| WO1998014072A1 (en) * | 1996-10-03 | 1998-04-09 | Taiyo Kagaku Co., Ltd. | Mineral composition |
| JP2001333736A (en) * | 2000-05-30 | 2001-12-04 | Taiyo Kagaku Co Ltd | Calcium composition having improved absorption efficiency |
| JP2002142720A (en) * | 2000-11-08 | 2002-05-21 | Otsuka Pharmaceut Factory Inc | Nutrition composition |
| JP2004018443A (en) * | 2002-06-14 | 2004-01-22 | Pigeon Corp | Enteric capsule |
| JP2005112753A (en) * | 2003-10-06 | 2005-04-28 | Sankyo:Kk | Soft capsule having improved bioavailability |
| JP2007191462A (en) * | 2005-12-19 | 2007-08-02 | Matsutani Chem Ind Ltd | Absorption promoter of mineral, food and fodder |
| JP2008086217A (en) * | 2006-09-29 | 2008-04-17 | Sanki Shoji Kk | healthy food |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015099102A1 (en) * | 2013-12-27 | 2015-07-02 | 富士フイルム株式会社 | Zinc-containing sleep-improving agent, non-rem sleep time-increasing agent, and sedative |
| CN105705144A (en) * | 2013-12-27 | 2016-06-22 | 富士胶片株式会社 | Zinc-containing sleep improving agent, non-rapid eye movement sleep time increasing agent and sedative |
| JPWO2015099102A1 (en) * | 2013-12-27 | 2017-03-23 | 富士フイルム株式会社 | Zinc-containing sleep improving agent, non-REM sleep time increasing agent and sedative |
| JPWO2015137357A1 (en) * | 2014-03-10 | 2017-04-06 | サラヤ株式会社 | Composition comprising sophorolipid, physiologically active substance and oil and fat, and method for producing the same |
| EP3117838A4 (en) * | 2014-03-10 | 2017-11-22 | Saraya Co., Ltd. | Composition containing sophorolipid, physiologically active substance and oil and fat, and method of producing said composition |
| US10307466B2 (en) | 2014-03-10 | 2019-06-04 | Saraya Co., Ltd. | Composition comprising sophorolipid, physiologically active substance and oil or fat, and method for producing the same |
| EP3117838B1 (en) | 2014-03-10 | 2020-09-16 | Saraya Co., Ltd. | Composition containing sophorolipid, physiologically active substance and oil and fat, and method of producing said composition |
| JP2016063771A (en) * | 2014-09-24 | 2016-04-28 | 日油株式会社 | Glycerophospholipid-containing powder and health food |
| JP2021001142A (en) * | 2019-06-21 | 2021-01-07 | 東洋カプセル株式会社 | Hydroxytyrosol-containing soft capsule agent |
| JP7360103B2 (en) | 2019-06-21 | 2023-10-12 | 東洋カプセル株式会社 | Soft capsules containing hydroxytyrosol |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ting et al. | Common delivery systems for enhancing in vivo bioavailability and biological efficacy of nutraceuticals | |
| US20230132388A9 (en) | Intact Pea Protein-Based Nutrient Composition | |
| ES2588241T3 (en) | Treatment of hyperglycemia with 25-hydroxyvitamin D3 and vitamin D | |
| WO2009101135A1 (en) | Combined use of 25-hydroxy-vitamin d3 and vitamin d3 for improving bone mineral density and for treating osteoporosis | |
| CN105613789A (en) | High-fat and high-dietary-fiber composite animal and plant powdered oil and preparation method and application thereof | |
| JP2016501037A (en) | Low viscosity, high caloric density oral nutritional compositions and related methods | |
| BRPI0711060A2 (en) | homogeneous dispersion containing citrus pulp and its applications | |
| WO2005061684A1 (en) | Fat composition | |
| KR20160148028A (en) | Formulation of fat-soluble vitamin | |
| WO2009101131A1 (en) | Treating hypertension with 25-hydroxyvitamin d3 | |
| WO2009096579A1 (en) | Nutritional composition for prevention of hyperglycemia | |
| JPWO2014030605A1 (en) | Nutritional composition | |
| EP2380582A1 (en) | Low-concentration nutritional composition | |
| JP2012036112A (en) | Method for manufacturing product for improving bioavailability, and the product | |
| JP2007308468A (en) | Basal metabolism increasing agent | |
| JP2019206518A (en) | Oil and fat-containing composition and oral preparation | |
| JP4437319B2 (en) | Preventing lactic acid production during exercise | |
| JP3981991B2 (en) | Aqueous emulsified nutritional composition and use thereof | |
| IL293452A (en) | Formulations comprising a mineral and/or a vitamin and a polysaccharide, compositions thereof and use thereof in supplementing said mineral and/or vitamin | |
| JP2005126405A (en) | Antiobesity drug | |
| CN110584120A (en) | Bone health composition | |
| TWI814232B (en) | gel nutritional composition | |
| WO2012119049A2 (en) | Nutritional compositions comprising prune extract and bioavailable curcumin | |
| JP6019577B2 (en) | Method for producing liquid emulsion composition | |
| JP4969989B2 (en) | Phospholipid composition, food composition containing the same, pharmaceutical composition, and method for producing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130716 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140819 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150113 |